14. Literaturverzeichnis – Chronische lymphatische Leukämie (CLL)

1. Robak, T, Puła, A, Braun, M, Robak, E, Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update., Ann Hematol, 2024. 103 (9)(9): p. 3369-3383., https://pubmed.ncbi.nlm.nih.gov/39052034/

2. National Cancer Institute (NIH), Cancer Stat Facts: Leukemia — Chronic Lymphocytic Leukemia (CLL), 2022., https://seer.cancer.gov/statfacts/html/clyl.html

3. Deutsche CLL Studiengruppe (DCLLSG), Was ist chronische lymphatische Leukämie (CLL)?, o.J.., https://dcllsg.de/cll_info/index.php

4. Robak, Tadeusz, Pula, Anna, Braun, Marcin, Robak, Ewa, Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update, 2024. 103: p. 1 - 15., https://www.researchgate.net/publication/382558945_Extramedullary_and_extranodal_manifestations_in_chronic_lymphocytic_leukemia_-_an_update

5. Guyatt, GH, Oxman, AD, Vist, GE, Kunz, R, Falck-Ytter, Y, Alonso-Coello, P, et.al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations., BMJ, 2008. 336 (7650)(7650): p. 924-6., https://pubmed.ncbi.nlm.nih.gov/18436948/

6. Balshem, H, Helfand, M, Schünemann, HJ, Oxman, AD, Kunz, R, Brozek, J, et.al. GRADE guidelines: 3. Rating the quality of evidence., J Clin Epidemiol, 2011. 64 (4)(4): p. 401-6., https://pubmed.ncbi.nlm.nih.gov/21208779/

7. Guyatt, GH, Oxman, AD, Vist, G, Kunz, R, Brozek, J, Alonso-Coello, P, et.al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)., J Clin Epidemiol, 2011. 64 (4)(4): p. 407-15., https://pubmed.ncbi.nlm.nih.gov/21247734/

8. Guyatt, GH, Oxman, AD, Kunz, R, Woodcock, J, Brozek, J, Helfand, M, et.al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency., J Clin Epidemiol, 2011. 64 (12)(12): p. 1294-302., https://pubmed.ncbi.nlm.nih.gov/21803546/

9. Guyatt, GH, Oxman, AD, Kunz, R, Brozek, J, Alonso-Coello, P, Rind, D, et.al. GRADE guidelines 6. Rating the quality of evidence--imprecision., J Clin Epidemiol, 2011. 64 (12)(12): p. 1283-93., https://pubmed.ncbi.nlm.nih.gov/21839614/

10. Guyatt, GH, Oxman, AD, Kunz, R, Woodcock, J, Brozek, J, Helfand, M, et.al. GRADE guidelines: 8. Rating the quality of evidence--indirectness., J Clin Epidemiol, 2011. 64 (12)(12): p. 1303-10., https://pubmed.ncbi.nlm.nih.gov/21802903/

11. Guyatt, GH, Oxman, AD, Montori, V, Vist, G, Kunz, R, Brozek, J, et.al. GRADE guidelines: 5. Rating the quality of evidence--publication bias., J Clin Epidemiol, 2011. 64 (12)(12): p. 1277-82., https://pubmed.ncbi.nlm.nih.gov/21802904/

12. Guyatt, GH, Oxman, AD, Sultan, S, Glasziou, P, Akl, EA, Alonso-Coello, P, et.al. GRADE guidelines: 9. Rating up the quality of evidence., J Clin Epidemiol, 2011. 64 (12)(12): p. 1311-6., https://pubmed.ncbi.nlm.nih.gov/21802902/

13. Hallek, M, Cheson, BD, Catovsky, D, Caligaris-Cappio, F, Dighiero, G, Döhner, H, et.al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL., Blood, 2018. 131 (25): p. 2745-2760., https://pubmed.ncbi.nlm.nih.gov/29540348/

14. Alaggio, Rita, Amador, Catalina, Anagnostopoulos, Ioannis, Attygalle, Ayoma D., Araujo, Iguaracyra Barreto de Oliveira, Berti, Emilio, et.al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms, 2022. 36(7): p. 1720 - 1748., https://doi.org/10.1038/s41375-022-01620-2

15. Oscier, D, Else, M, Matutes, E, Morilla, R, Strefford, JC, Catovsky, D, The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial., Br J Haematol, 2016. 174 (5): p. 767-75., https://pubmed.ncbi.nlm.nih.gov/27151266/

16. Rawstron, AC, Kreuzer, KA, Soosapilla, A, Spacek, M, Stehlikova, O, Gambell, P, et.al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project., Cytometry B Clin Cytom, 2018. 94 (1): p. 121-128., https://pubmed.ncbi.nlm.nih.gov/29024461/

17. Böttcher, S, Engelmann, R, Grigore, G, Fernandez, P, Caetano, J, Flores-Montero, J, et.al. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study., Blood Adv, 2022. 6 (3): p. 976-992., https://pubmed.ncbi.nlm.nih.gov/34814179/

18. Haferlach, C., Bacher, U., Cytogenetic methods in chronic lymphocytic leukemia, Methods Mol Biol, 2011. 730: p. 119-30., https://www.ncbi.nlm.nih.gov/pubmed/21431638

19. Strati, P, Shanafelt, TD, Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification., Blood, 2015. 126 (4): p. 454-62., https://pubmed.ncbi.nlm.nih.gov/26065657/

20. Shanafelt, T. D., Ghia, P., Lanasa, M. C., Landgren, O., Rawstron, A. C., Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management, Leukemia, 2010. 24 (3): p. 512-20., https://www.ncbi.nlm.nih.gov/pubmed/20090778

21. Rawstron, AC, Bennett, FL, O'Connor, SJ, Kwok, M, Fenton, JA, Plummer, M, et.al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia., N Engl J Med, 2008. 359 (6): p. 575-83., https://pubmed.ncbi.nlm.nih.gov/18687638/

22. Chow, KU, Luxembourg, B, Seifried, E, Bonig, H, Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200 Healthy Individuals., Radiology, 2016. 279 (1): p. 306-13., https://pubmed.ncbi.nlm.nih.gov/26509293/

23. Goldin, L. R., Bjorkholm, M., Kristinsson, S. Y., Turesson, I., Landgren, O., Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia, Haematologica, 2009. 94 (5): p. 647-53., https://www.ncbi.nlm.nih.gov/pubmed/19286886

24. Kleinstern, G, Camp, NJ, Goldin, LR, Vachon, CM, Vajdic, CM, de Sanjose, S, et.al. Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis., Blood, 2018. 131 (23): p. 2541-2551., https://pubmed.ncbi.nlm.nih.gov/29674426/

25. Parikh, SA, Strati, P, Tsang, M, West, CP, Shanafelt, TD, Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis., Blood, 2016. 127 (14): p. 1752-60., https://pubmed.ncbi.nlm.nih.gov/26841802/

26. International, C. L. L. I. P. I. working group, An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data, Lancet Oncol, 2016. 17 (6): p. 779-90., https://www.ncbi.nlm.nih.gov/pubmed/27185642

27. Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., et.al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis, Cancer, 1981. 48: p. 198-206., https://www.ncbi.nlm.nih.gov/pubmed/7237385

28. Parikh, S. A., Shanafelt, T. D., Prognostic factors and risk stratification in chronic lymphocytic leukemia, Semin Oncol, 2016. 43 (2): p. 233-40., https://www.ncbi.nlm.nih.gov/pubmed/27040701

29. Hoechstetter, MA, Busch, R, Eichhorst, B, Bühler, A, Winkler, D, Bahlo, J, et.al. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group., Leukemia, 2020. 34 (4): p. 1038-1051., https://pubmed.ncbi.nlm.nih.gov/32042081/

30. Gentile, M, Shanafelt, TD, Rossi, D, Laurenti, L, Mauro, FR, Molica, S, et.al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients., Blood, 2016. 128 (16): p. 2093-2095., https://pubmed.ncbi.nlm.nih.gov/27549308/

31. Molica, S, Shanafelt, TD, Giannarelli, D, Gentile, M, Mirabelli, R, Cutrona, G, et.al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients., Am J Hematol, 2016. 91 (11): p. 1090-1095., https://pubmed.ncbi.nlm.nih.gov/27465919/

32. da Cunha-Bang, C, Christiansen, I, Niemann, CU, The CLL-IPI applied in a population-based cohort., Blood, 2016. 128 (17): p. 2181-2183., https://pubmed.ncbi.nlm.nih.gov/27605511/

33. Parikh, SA, Rabe, KG, Kay, NE, Call, TG, Ding, W, Leis, JF, et.al. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL., Blood, 2021. 138 (2): p. 149-159., https://pubmed.ncbi.nlm.nih.gov/33876228/

34. Rotbain, EC, da Cunha-Bang, C, Brieghel, C, Niemann, CU, CLL-IPI applied in Binet A CLL: a nationwide cohort study., Blood Adv, 2022. 6 (21): p. 5698-5701., https://pubmed.ncbi.nlm.nih.gov/35090168/

35. van der Velden, NCA, Meijers, MC, Han, PKJ, van Laarhoven, HWM, Smets, EMA, Henselmans, I, The Effect of Prognostic Communication on Patient Outcomes in Palliative Cancer Care: a Systematic Review., Curr Treat Options Oncol, 2020. 21 (5): p. 40., https://pubmed.ncbi.nlm.nih.gov/32328821/

36. LeBlanc, TW, Marron, JM, Ganai, S, McGinnis, MM, Spence, RA, Tenner, L, et.al. Prognostication and Communication in Oncology., J Oncol Pract, 2019. 15 (4): p. 208-215., https://pubmed.ncbi.nlm.nih.gov/30908141/

37. Gray, TF, Temel, JS, El-Jawahri, A, Illness and prognostic understanding in patients with hematologic malignancies., Blood Rev, 2021. 45: p. 100692., https://pubmed.ncbi.nlm.nih.gov/32284227/

38. Baumann, T, Moia, R, Gaidano, G, Delgado, J, Condoluci, A, Villamor, N, et.al. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients., Leukemia, 2021. 35 (8): p. 2325-2331., https://pubmed.ncbi.nlm.nih.gov/33542480/

39. Baumann, Tycho, Moia, Riccardo, Gaidano, Gianluca, Delgado, Julio, Condoluci, Adalgisa, Villamor, Neus, et.al. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients, 2021. 35(8): p. 2325 - 2331., https://doi.org/10.1038/s41375-021-01149-w

40. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., et.al. Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 1982. 5 (6): p. 649-55., https://www.ncbi.nlm.nih.gov/pubmed/7165009

41. AWMF (Arbeitsgemeinschaft Wissenschaftlich medizinischer Fachgesellschaften). Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion, AWMF-Registernummer: 021/011 (Stand: Januar 2011), 2011.

42. Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillaume, Döhner, Hartmut, et.al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines, 2008. 111(12): p. 5446 - 5456., https://doi.org/10.1182/blood-2007-06-093906

43. Cockcroft, D. W., Gault, M. H., Prediction of creatinine clearance from serum creatinine, Nephron, 1976. 16 (1): p. 31-41., https://www.ncbi.nlm.nih.gov/pubmed/1244564

44. Falchi, L., Keating, M. J., Marom, E. M., Truong, M. T., Schlette, E. J., Sargent, R. L., et.al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia, Blood, 2014. 123 (18): p. 2783-90., https://www.ncbi.nlm.nih.gov/pubmed/24615780

45. Papajik, T., Myslivecek, M., Urbanova, R., Buriankova, E., Kapitanova, Z., Prochazka, V., et.al. 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation, Leuk Lymphoma, 2014. 55 (2): p. 314-9., https://www.ncbi.nlm.nih.gov/pubmed/23656196

46. Baliakas, P., Iskas, M., Gardiner, A., Davis, Z., Plevova, K., Nguyen-Khac, F., et.al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data, Am J Hematol, 2014. 89: p. 249-55., https://www.ncbi.nlm.nih.gov/pubmed/24166834

47. Mayr, C., Speicher, M. R., Kofler, D. M., Buhmann, R., Strehl, J., Busch, R., et.al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia, Blood, 2006. 107 (2): p. 742-51., https://www.ncbi.nlm.nih.gov/pubmed/16179374

48. Herling, C. D., Klaumunzer, M., Rocha, C. K., Altmuller, J., Thiele, H., Bahlo, J., et.al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy, Blood, 2016. 128 (3): p. 395-404., https://www.ncbi.nlm.nih.gov/pubmed/27226433

49. Jarošová, M, Plevová, K, Kotašková, J, Doubek, M, Pospíšilová, Š, The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature., Leuk Lymphoma, 2019. 60 (10): p. 2348-2355., https://pubmed.ncbi.nlm.nih.gov/30773964/

50. Baliakas, P, Jeromin, S, Iskas, M, Puiggros, A, Plevova, K, Nguyen-Khac, F, et.al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact., Blood, 2019. 133 (11): p. 1205-1216., https://pubmed.ncbi.nlm.nih.gov/30602617/

51. Al-Sawaf, O, Lilienweiss, E, Bahlo, J, Robrecht, S, Fink, AM, Patz, M, et.al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia., Blood, 2020. 135 (11): p. 866-870., https://pubmed.ncbi.nlm.nih.gov/31990291/

52. Fürstenau, M, Thus, YJ, Robrecht, S, Mellink, CHM, van der Kevie-Kersemaekers, AM, Dubois, J, et.al. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations., Blood, 2023. 142 (5): p. 446-459., https://pubmed.ncbi.nlm.nih.gov/37172204/

53. Baliakas, P, Espinet, B, Mellink, C, Jarosova, M, Athanasiadou, A, Ghia, P, et.al. Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations., Hemasphere, 2022. 6 (4): p. e707., https://pubmed.ncbi.nlm.nih.gov/35392482/

54. Thompson, PA, O'Brien, SM, Wierda, WG, Ferrajoli, A, Stingo, F, Smith, SC, et.al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens., Cancer, 2015. 121 (20): p. 3612-21., https://pubmed.ncbi.nlm.nih.gov/26193999/

55. Munir, Talha, Brown, Jennifer R., O'Brien, Susan, Barrientos, Jacqueline C., Barr, Paul M., Reddy, Nishitha M., et.al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaJohn Wiley & Sons, Ltd, American Journal of Hematology, 2019. 94(12): p. 1353 - 1363., https://doi.org/10.1002/ajh.25638

56. Ramos-Campoy, S, Puiggros, A, Beà, S, Bougeon, S, Larráyoz, MJ, Costa, D, et.al. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients., Haematologica, 2022. 107 (3): p. 593-603., https://pubmed.ncbi.nlm.nih.gov/33691382/

57. Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., et.al. Genomic aberrations and survival in chronic lymphocytic leukemia, N Engl J Med, 2000. 343 (26): p. 1910-6., https://www.ncbi.nlm.nih.gov/pubmed/11136261

58. Campo, E, Cymbalista, F, Ghia, P, Jäger, U, Pospisilova, S, Rosenquist, R, et.al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics, Haematologica, 2018. 103 (12): p. 1956-1968., https://pubmed.ncbi.nlm.nih.gov/30442727/

59. Stilgenbauer, S., Schnaiter, A., Paschka, P., Zenz, T., Rossi, M., Dohner, K., et.al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial, Blood, 2014. 123 (21): p. 3247-54., https://www.ncbi.nlm.nih.gov/pubmed/24652989

60. Fischer, K, Al-Sawaf, O, Bahlo, J, Fink, AM, Tandon, M, Dixon, M, et.al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions., N Engl J Med, 2019. 380 (23): p. 2225-2236., https://pubmed.ncbi.nlm.nih.gov/31166681/

61. Tausch, E, Beck, P, Schlenk, RF, Jebaraj, BJ, Dolnik, A, Yosifov, DY, et.al. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1., Haematologica, 2020. 105 (10): p. 2440-2447., https://pubmed.ncbi.nlm.nih.gov/33054084/

62. Barr, PM, Owen, C, Robak, T, Tedeschi, A, Bairey, O, Burger, JA, et.al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia., Blood Adv, 2022. 6 (11): p. 3440-3450., https://pubmed.ncbi.nlm.nih.gov/35377947/

63. Tausch, E, Schneider, C, Robrecht, S, Zhang, C, Dolnik, A, Bloehdorn, J, et.al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax., Blood, 2020. 135 (26)(26): p. 2402-2412., https://pubmed.ncbi.nlm.nih.gov/32206772/

64. Knisbacher, BA, Lin, Z, Hahn, CK, Nadeu, F, Duran-Ferrer, M, Stevenson, KE, et.al. Molecular map of chronic lymphocytic leukemia and its impact on outcome., Nat Genet, 2022. 54 (11): p. 1664-1674., https://pubmed.ncbi.nlm.nih.gov/35927489/

65. Sanger, F., Coulson, A. R., A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase, J Mol Biol, 1975. 94 (3): p. 441-8., https://www.ncbi.nlm.nih.gov/pubmed/1100841

66. Zenz, T., Mertens, D., Kuppers, R., Dohner, H., Stilgenbauer, S., From pathogenesis to treatment of chronic lymphocytic leukaemia, Nat Rev Cancer, 2010. 10 (1): p. 37-50., https://www.ncbi.nlm.nih.gov/pubmed/19956173

67. Malcikova, J, Pavlova, S, Kunt Vonkova, B, Radova, L, Plevova, K, Kotaskova, J, et.al. Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options., Blood, 2021. 138 (25): p. 2670-2685., https://pubmed.ncbi.nlm.nih.gov/33945616/

68. Blakemore, SJ, Clifford, R, Parker, H, Antoniou, P, Stec-Dziedzic, E, Larrayoz, M, et.al. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial., Leukemia, 2020. 34 (7): p. 1760-1774., https://pubmed.ncbi.nlm.nih.gov/32015491/

69. Baghaei Vaji, F, Boroumand Nasr, A, Rezvani, A, Ayatollahi, H, Goudarzi, S, Lavasani, S, et.al. Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis., Leuk Res, 2021. 111: p. 106729., https://pubmed.ncbi.nlm.nih.gov/34735935/

70. Condoluci, A, Terzi di Bergamo, L, Langerbeins, P, Hoechstetter, MA, Herling, CD, De Paoli, L, et.al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia., Blood, 2020. 135 (21): p. 1859-1869., https://pubmed.ncbi.nlm.nih.gov/32267500/

71. Blombery, P, Anderson, MA, Gong, JN, Thijssen, R, Birkinshaw, RW, Thompson, ER, et.al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia., Cancer Discov, 2019. 9 (3): p. 342-353., https://pubmed.ncbi.nlm.nih.gov/30514704/

72. Wang, E, Mi, X, Thompson, MC, Montoya, S, Notti, RQ, Afaghani, J, et.al. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors., N Engl J Med, 2022. 386 (8): p. 735-743., https://pubmed.ncbi.nlm.nih.gov/35196427/

73. Woyach, J.A., Ruppert, AS, Guinn, D, Lehman, A, Blachly, JS, Lozanski, A, et.al. BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia, J Clin Oncol, 2017. 35 (13): p. 1437-1443., https://pubmed.ncbi.nlm.nih.gov/28418267/

74. Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., et.al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, 1999. 94 (6): p. 1840-7., https://www.ncbi.nlm.nih.gov/pubmed/10477712

75. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., Stevenson, F. K., Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia, Blood, 1999. 94 (6): p. 1848-54., https://www.ncbi.nlm.nih.gov/pubmed/10477713

76. Sharman, JP, Egyed, M, Jurczak, W, Skarbnik, A, Pagel, JM, Flinn, IW, et.al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia., Leukemia, 2022. 36 (4): p. 1171-1175., https://pubmed.ncbi.nlm.nih.gov/34974526/

77. Al-Sawaf, O, Zhang, C, Jin, HY, Robrecht, S, Choi, Y, Balasubramanian, S, et.al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia., Nat Commun, 2023. 14 (1): p. 2147., https://pubmed.ncbi.nlm.nih.gov/37072421/

78. Agathangelidis, A, Darzentas, N, Hadzidimitriou, A, Brochet, X, Murray, F, Yan, XJ, et.al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies., Blood, 2012. 119 (19): p. 4467-75., https://pubmed.ncbi.nlm.nih.gov/22415752/

79. Jaramillo, S, Agathangelidis, A, Schneider, C, Bahlo, J, Robrecht, S, Tausch, E, et.al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)., Haematologica, 2020. 105 (11): p. 2598-2607., https://pubmed.ncbi.nlm.nih.gov/33131249/

80. Abrisqueta, P., Villamor, N., Terol, M. J., Gonzalez-Barca, E., Gonzalez, M., Ferra, C., et.al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia, Blood, 2013. 122: p. 3951-9., https://www.ncbi.nlm.nih.gov/pubmed/24124086

81. Fischer, K., Cramer, P., Busch, R., Bottcher, S., Bahlo, J., Schubert, J., et.al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group, J Clin Oncol, 2012. 30 (26): p. 3209-16., https://www.ncbi.nlm.nih.gov/pubmed/22869884

82. Strati, P., Keating, M. J., O'Brien, S. M., Ferrajoli, A., Burger, J., Faderl, S., et.al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion, Haematologica, 2014. 99 (8): p. 1350-5., https://www.ncbi.nlm.nih.gov/pubmed/24859876

83. Thompson, PA, Tam, CS, O'Brien, SM, Wierda, WG, Stingo, F, Plunkett, W, et.al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia., Blood, 2016. 127 (3): p. 303-9., https://pubmed.ncbi.nlm.nih.gov/26492934/

84. Bottcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., et.al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial, J Clin Oncol, 2012. 30: p. 980-8., https://www.ncbi.nlm.nih.gov/pubmed/22331940

85. Greil, R, Obrtlíková, P, Smolej, L, Kozák, T, Steurer, M, Andel, J, et.al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial., Lancet Haematol, 2016. 3 (7): p. e317-29., https://pubmed.ncbi.nlm.nih.gov/27374465/

86. Kovacs, G., Robrecht, S., Fink, A. M., Bahlo, J., Cramer, P., von Tresckow, J., et.al. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group, J Clin Oncol, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27573660

87. Santacruz, R, Villamor, N, Aymerich, M, Martínez-Trillos, A, López, C, Navarro, A, et.al. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy., Haematologica, 2014. 99 (5): p. 873-80., https://pubmed.ncbi.nlm.nih.gov/24700492/

88. Moreton, P, Kennedy, B, Lucas, G, Leach, M, Rassam, SM, Haynes, A, et.al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival., J Clin Oncol, 2005. 23 (13): p. 2971-9., https://pubmed.ncbi.nlm.nih.gov/15738539/

89. Fraser, G, Cramer, P, Demirkan, F, Silva, RS, Grosicki, S, Pristupa, A, et.al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma., Leukemia, 2019. 33 (4): p. 969-980., https://pubmed.ncbi.nlm.nih.gov/30315239/

90. Stilgenbauer, S, Eichhorst, B, Schetelig, J, Hillmen, P, Seymour, JF, Coutre, S, et.al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial., J Clin Oncol, 2018. 36 (19): p. 1973-1980., https://pubmed.ncbi.nlm.nih.gov/29715056/

91. Kwok, M, Rawstron, AC, Varghese, A, Evans, PA, O'Connor, SJ, Doughty, C, et.al. Minimal residual disease is an independent predictor for 10-year survival in CLL., Blood, 2016. 128 (24): p. 2770-2773., https://pubmed.ncbi.nlm.nih.gov/27697770/

92. Seymour, JF, Kipps, TJ, Eichhorst, BF, D'Rozario, J, Owen, CJ, Assouline, S, et.al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab., Blood, 2022. 140 (8): p. 839-850., https://pubmed.ncbi.nlm.nih.gov/35605176/

93. Langerak, AW, Ritgen, M, Goede, V, Robrecht, S, Bahlo, J, Fischer, K, et.al. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab., Blood, 2019. 133 (5): p. 494-497., https://pubmed.ncbi.nlm.nih.gov/30455380/

94. Al-Sawaf, O, Zhang, C, Lu, T, Liao, MZ, Panchal, A, Robrecht, S, et.al. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study., J Clin Oncol, 2021. 39 (36): p. 4049-4060., https://pubmed.ncbi.nlm.nih.gov/34709929/

95. Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, et.al. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia, 2021. 35(6): p. 1597 - 1609., https://doi.org/10.1038/s41375-020-01009-z

96. Herling, CD, Cymbalista, F, Groß-Ophoff-Müller, C, Bahlo, J, Robrecht, S, Langerbeins, P, et.al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial., Leukemia, 2020. 34 (8): p. 2038-2050., https://pubmed.ncbi.nlm.nih.gov/32071431/

97. Wang, XV, Hanson, CA, Tschumper, RC, Lesnick, CE, Braggio, E, Paietta, EM, et.al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib., Blood, 2021. 138 (26): p. 2810-2827., https://pubmed.ncbi.nlm.nih.gov/34407545/

98. Thompson, PA, Srivastava, J, Peterson, C, Strati, P, Jorgensen, JL, Hether, T, et.al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy., Blood, 2019. 134 (22): p. 1951-1959., https://pubmed.ncbi.nlm.nih.gov/31537528/

99. Hengeveld, PJ, van der Klift, MY, Kolijn, PM, Davi, F, Kavelaars, FG, de Jonge, E, et.al. Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL., Blood, 2023. 141 (5): p. 519-528., https://pubmed.ncbi.nlm.nih.gov/36084320/

100. Simon, F., Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study GroupBlood, 2023. 142 (Supplement 1): p. 1901., https://doi.org/10.1182/blood-2023-178597

101. Michallet, AS, Letestu, R, Le Garff-Tavernier, M, Aanei, C, Ticchioni, M, Dilhuydy, MS, et.al. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial., Blood, 2021. 137 (8): p. 1019-1023., https://pubmed.ncbi.nlm.nih.gov/33167024/

102. Munir, T, Emmerson, J, Hockaday, A, Oughton, JB, Howard, D, Phillips, D, et.al. Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial., Br J Haematol, 2022. 199 (5): p. 707-719., https://pubmed.ncbi.nlm.nih.gov/36017875/

103. Wierda, WG, Allan, JN, Siddiqi, T, Kipps, TJ, Opat, S, Tedeschi, A, et.al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study., J Clin Oncol, 2021. 39 (34): p. 3853-3865., https://pubmed.ncbi.nlm.nih.gov/34618601/

104. Kater, AP, Levin, MD, Dubois, J, Kersting, S, Enggaard, L, Veldhuis, GJ, et.al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial., Lancet Oncol, 2022. 23 (6): p. 818-828., https://pubmed.ncbi.nlm.nih.gov/35654052/

105. Hillmen, P, Rawstron, AC, Brock, K, Muñoz-Vicente, S, Yates, FJ, Bishop, R, et.al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study., J Clin Oncol, 2019. 37 (30): p. 2722-2729., https://pubmed.ncbi.nlm.nih.gov/31295041/

106. Munir, T, Cairns, DA, Bloor, A, Allsup, D, Cwynarski, K, Pettitt, A, et.al. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease., N Engl J Med, 2023., https://pubmed.ncbi.nlm.nih.gov/38078508/

107. Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, et.al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study., Leukemia, 2016. 30 (4): p. 929-36., https://pubmed.ncbi.nlm.nih.gov/26639181/

108. van der Velden, V. H., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E. R., et.al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data, Leukemia, 2007. 21 (4): p. 604-11., https://www.ncbi.nlm.nih.gov/pubmed/17287850

109. Bottcher, S., Stilgenbauer, S., Busch, R., Bruggemann, M., Raff, T., Pott, C., et.al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis, Leukemia, 2009. 23: p. 2007-17., https://www.ncbi.nlm.nih.gov/pubmed/19641522

110. Institute of Medicine Committee on Psychosocial Services to Cancer Patients/Families in a Community, S., The National Academies Collection: Reports funded by National Institutes of Health, in Cancer Care for the Whole Patient: Meeting Psychosocial Health NeedsNational Academies Press (US), 2008.

111. AWMF (Arbeitsgemeinschaft Wissenschaftlich medizinischer Fachgesellschaften). Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), S3-Leitlinie, Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, AWMF-Registernummer: 032/051OL (Stand: Januar 2014), 2014.

112. Kusch, M., Labouvie, H., Hein-Nau, B., Schwarzkamp, U., Wolf, J., Hallek, M., Integrierte Psychoonkologie am Centrum für Integrierte Onkologie Koeln Bonn, Dtsch Med Wochenschr, 2014. 139(46): p. 2357-60.

113. Kusch, M., Labouvie, H., Hein-Nau, B., Klinische Psychoonkologie, Springer, Heidelberg, 2013., https://link.springer.com/book/10.1007/978-3-642-31748-4

114. Pirl, W. F., Fann, J. R., Greer, J. A., Braun, I., Deshields, T., Fulcher, C., et.al. Recommendations for the implementation of distress screening programs in cancer centers: report from the American Psychosocial Oncology Society (APOS), Association of Oncology Social Work (AOSW), and Oncology Nursing Society (ONS) joint task force, Cancer, 2014. 120 (19): p. 2946-54., https://www.ncbi.nlm.nih.gov/pubmed/24798107

115. Donovan, K. A., Grassi, L., McGinty, H. L., Jacobsen, P. B., Validation of the distress thermometer worldwide: state of the science, Psychooncology, 2014. 23 (3): p. 241-50., https://www.ncbi.nlm.nih.gov/pubmed/25160838

116. Andersen, B. L., DeRubeis, R. J., Berman, B. S., Gruman, J., Champion, V. L., Massie, M. J., et.al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation, J Clin Oncol, 2014. 32: p. 1605-19., https://www.ncbi.nlm.nih.gov/pubmed/24733793

117. Kovacs, G, Böttcher, S., Bahlo, J, Kluth, S, Ritgen, M., Fink, A-M, et.al. Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG), Blood, 2014. 124 (21): p. Abstract 23., https://ashpublications.org/blood/article/124/21/23/89826/Value-of-Minimal-Residual-Disease-MRD-Negative

118. Tam, CS, Brown, JR, Kahl, BS, Ghia, P, Giannopoulos, K, Jurczak, W, et.al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial., Lancet Oncol, 2022. 23 (8): p. 1031-1043., https://pubmed.ncbi.nlm.nih.gov/35810754/

119. Sharman, JP, Egyed, M, Jurczak, W, Skarbnik, A, Pagel, JM, Flinn, IW, et.al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial., Lancet, 2020. 395 (10232): p. 1278-1291., https://pubmed.ncbi.nlm.nih.gov/32305093/

120. Woyach, J.A., Ruppert, AS, Heerema, NA, Zhao, W, Booth, AM, Ding, W, et.al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL., N Engl J Med, 2018. 379 (26): p. 2517-2528., https://pubmed.ncbi.nlm.nih.gov/30501481/

121. Moreno, C, Greil, R, Demirkan, F, Tedeschi, A, Anz, B, Larratt, L, et.al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial., Lancet Oncol, 2019. 20 (1): p. 43-56., https://pubmed.ncbi.nlm.nih.gov/30522969/

122. Shanafelt, TD, Wang, XV, Kay, NE, Hanson, CA, O'Brien, S, Barrientos, J, et.al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia., N Engl J Med, 2019. 381 (5): p. 432-443., https://pubmed.ncbi.nlm.nih.gov/31365801/

123. Eichhorst, B., Simon, F., Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail), 2022.

124. Shanafelt, TD, Wang, XV, Hanson, CA, Paietta, EM, O'Brien, S, Barrientos, J, et.al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial., Blood, 2022. 140 (2): p. 112-120., https://pubmed.ncbi.nlm.nih.gov/35427411/

125. Awan, FT, Addison, D, Alfraih, F, Baratta, SJ, Campos, RN, Cugliari, MS, et.al. International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL., Blood Adv, 2022. 6 (18): p. 5516-5525., https://pubmed.ncbi.nlm.nih.gov/35790105/

126. Bhat, SA, Gambril, J, Azali, L, Chen, ST, Rosen, L, Palettas, M, et.al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation., Blood, 2022. 140 (20): p. 2142-2145., https://pubmed.ncbi.nlm.nih.gov/35917449/

127. Lampson, BL, Yu, L, Glynn, RJ, Barrientos, JC, Jacobsen, ED, Banerji, V, et.al. Ventricular arrhythmias and sudden death in patients taking ibrutinib., Blood, 2017. 129 (18): p. 2581-2584., https://pubmed.ncbi.nlm.nih.gov/28223277/

128. Brown, JR, Eichhorst, B, Hillmen, P, Jurczak, W, Kaźmierczak, M, Lamanna, N, et.al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, N Engl J Med, 2022. 388 (4): p. 319-332., https://pubmed.ncbi.nlm.nih.gov/36511784/

129. Byrd, JC, Hillmen, P, Ghia, P, Kater, AP, Chanan-Khan, A, Furman, RR, et.al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial., J Clin Oncol, 2021. 39 (31): p. 3441-3452., https://pubmed.ncbi.nlm.nih.gov/34310172/

130. Kater, Arnon, Owen, Carolyn, Moreno, Carol, Follows, George, Bch, B, Munir, Talha, et.al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities, 2022., https://doi.org/10.1056/EVIDoa2200006

131. Eichhorst, B, Niemann, CU, Kater, AP, Fürstenau, M, von Tresckow, J, Zhang, C, et.al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia., N Engl J Med, 2023. 388 (19): p. 1739-1754., https://pubmed.ncbi.nlm.nih.gov/37163621/

132. Tam, CS, Allan, JN, Siddiqi, T, Kipps, TJ, Jacobs, R, Opat, S, et.al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort., Blood, 2022. 139 (22): p. 3278-3289., https://pubmed.ncbi.nlm.nih.gov/35196370/

133. Thompson, MC, Harrup, RA, Coombs, CC, Roeker, LE, Pu, JJ, Choi, MY, et.al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen., Blood Adv, 2022. 6 (15): p. 4553-4557., https://pubmed.ncbi.nlm.nih.gov/35736670/

134. Ma, S, Seymour, JF, Brander, DM, Kipps, TJ, Choi, MY, Anderson, MA, et.al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy., Blood, 2021. 138 (10): p. 836-846., https://pubmed.ncbi.nlm.nih.gov/34115103/

135. Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., et.al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia, N Engl J Med, 2015. 373: p. 2425-37., https://www.ncbi.nlm.nih.gov/pubmed/26639149

136. Ahn, I.E., Tian, X, Ipe, D, Cheng, M, Albitar, M, Tsao, LC, et.al. Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model., J Clin Oncol, 2021. 39 (6): p. 576-585., https://pubmed.ncbi.nlm.nih.gov/33026937/

137. Munir, Talha, Pitchford, Alexandra, Bloor, Adrian, Broom, Angus, Young, Moya, Kennedy, Daniel, et.al. Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial, 2021. 138: p. 2636 - 2636., https://doi.org/10.1182/blood-2021-152167

138. Lyon, AR, López-Fernández, T, Couch, LS, Asteggiano, R, Aznar, MC, Bergler-Klein, J, et.al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)., Eur Heart J Cardiovasc Imaging, 2022. 23 (10): p. e333-e465., https://pubmed.ncbi.nlm.nih.gov/36017575/

139. Woyach, Jennifer, Huang, Ying, Rogers, Kerry, Bhat, Seema, Grever, Michael, Lozanski, Arletta, et.al. Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK MutationsBlood, 2019. 134: p. 504., https://doi.org/10.1182/blood-2019-127674

140. Quinquenel, A, Fornecker, LM, Letestu, R, Ysebaert, L, Fleury, C, Lazarian, G, et.al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study, Blood, 2019. 134 (7): p. 641-644., https://pubmed.ncbi.nlm.nih.gov/31243043/

141. Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., et.al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial, Blood, 2016. 127 (2): p. 208-15., https://www.ncbi.nlm.nih.gov/pubmed/26486789

142. Thompson, PA, Bazinet, A, Wierda, WG, Tam, CS, O'Brien, SM, Saha, S, et.al. Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up., Blood, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/37595283/

143. Carney, DA, Westerman, DA, Tam, CS, Milner, A, Prince, HM, Kenealy, M, et.al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy., Leukemia, 2010. 24 (12): p. 2056-62., https://pubmed.ncbi.nlm.nih.gov/20962860/

144. da Cunha-Bang, C, Rostgaard, K, Andersen, MA, Rotbain, EC, Grønbaek, K, Frederiksen, H, et.al. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study., Br J Haematol, 2021. 193 (2): p. 339-345., https://pubmed.ncbi.nlm.nih.gov/33570184/

145. Benjamini, O, Jain, P, Trinh, L, Qiao, W, Strom, SS, Lerner, S, et.al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes., Leuk Lymphoma, 2015. 56 (6): p. 1643-50., https://pubmed.ncbi.nlm.nih.gov/25308294/

146. Bergmann, Manuela A., Busch, Raymonde, Eichhorst, Barbara, Buehler, Andreas, Fischer, Norbert, Eckart, Michael J, et.al. Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG), 2013. 122(21): p. 4127 - 4127., https://doi.org/10.1182/blood.V122.21.4127.4127

147. Schweighofer, C., Levy, V., Mueller, C., Busch, R., Porcher, R., Ibach, S., et.al. Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial, Blood, 2013. 122 (21): p. Abstract 524., https://ashpublications.org/blood/article/122/21/524/112931/Early-Versus-Deferred-Treatment-With-Combined

148. Langerbeins, P, Zhang, C, Robrecht, S, Cramer, P, Fürstenau, M, Al-Sawaf, O, et.al. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia., Blood, 2022. 139 (2): p. 177-187., https://pubmed.ncbi.nlm.nih.gov/34758069/

149. Cramer, P, Fürstenau, M, Robrecht, S, Giza, A, Zhang, C, Fink, AM, et.al. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial., Lancet Haematol, 2022. 9 (10): p. e745-e755., https://pubmed.ncbi.nlm.nih.gov/35988545/

150. Cramer, P, Tresckow, JV, Robrecht, S, Bahlo, J, Fürstenau, M, Langerbeins, P, et.al. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial., Haematologica, 2021. 106 (2): p. 543-554., https://pubmed.ncbi.nlm.nih.gov/32107341/

151. Cramer, P, von Tresckow, J, Bahlo, J, Robrecht, S, Langerbeins, P, Al-Sawaf, O, et.al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial., Lancet Oncol, 2018. 19 (9): p. 1215-1228., https://pubmed.ncbi.nlm.nih.gov/30115596/

152. von Tresckow, J, Cramer, P, Robrecht, S, Langerbeins, P, Fink, AM, Al-Sawaf, O, et.al. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial., Leukemia, 2022. 36 (8)(8): p. 2125-2128., https://pubmed.ncbi.nlm.nih.gov/35752657/

153. Huber, H, Edenhofer, S, von Tresckow, J, Robrecht, S, Zhang, C, Tausch, E, et.al. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia., Blood, 2022. 139 (9): p. 1318-1329., https://pubmed.ncbi.nlm.nih.gov/35108374/

154. Soumerai, JD, Mato, AR, Dogan, A, Seshan, VE, Joffe, E, Flaherty, K, et.al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial., Lancet Haematol, 2021. 8 (12): p. e879-e890., https://pubmed.ncbi.nlm.nih.gov/34826411/

155. Cramer, P, Tausch, E, von Tresckow, J, Giza, A, Robrecht, S, Schneider, C, et.al. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations., Blood, 2021. 138 (19): p. 1805-1816., https://pubmed.ncbi.nlm.nih.gov/34086865/

156. Blum, K. A., Young, D., Broering, S., Lucas, M. S., Fischer, B., Lin, T. S., et.al. Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria, J Clin Oncol, 2007. 25: p. 5624-9., https://www.ncbi.nlm.nih.gov/pubmed/17984187

157. Ghia, P, Pluta, A, Wach, M, Lysak, D, Kozak, T, Simkovic, M, et.al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia., J Clin Oncol, 2020. 38 (25): p. 2849-2861., https://pubmed.ncbi.nlm.nih.gov/32459600/

158. Hillmen, P, Eichhorst, B, Brown, JR, Lamanna, N, O'Brien, SM, Tam, CS, et.al. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial., J Clin Oncol, 2023. 41 (5): p. 1035-1045., https://pubmed.ncbi.nlm.nih.gov/36395435/

159. Seymour, JF, Kipps, TJ, Eichhorst, B, Hillmen, P, D'Rozario, J, Assouline, S, et.al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia., N Engl J Med, 2018. 378 (12): p. 1107-1120., https://pubmed.ncbi.nlm.nih.gov/29562156/

160. Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., et.al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, N Engl J Med, 2014. 371 (3): p. 213-223., https://www.ncbi.nlm.nih.gov/pubmed/24881631

161. Brown, Jennifer R., Hillmen, Peter, O'Brien, Susan, Barrientos, Jaqueline C., Reddy, Nishitha, Coutre, Steven, et.al. Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE^TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Blood, 2014. 124 (21): p. 3331., https://doi.org/10.1182/blood.V124.21.3331.3331

162. Farooqui, M. Z., Valdez, J., Martyr, S., Aue, G., Saba, N., Niemann, C. U., et.al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial, Lancet Oncol, 2015. 16 (2): p. 169-76., https://www.ncbi.nlm.nih.gov/pubmed/25555420

163. Byrd, JC, Furman, RR, Coutre, SE, Burger, JA, Blum, KA, Coleman, M, et.al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib., Blood, 2015. 125 (16): p. 2497-506., https://pubmed.ncbi.nlm.nih.gov/25700432/

164. Jones, JA, Robak, T, Brown, JR, Awan, FT, Badoux, X, Coutre, S, et.al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial., Lancet Haematol, 2017. 4 (3): p. e114-e126., https://pubmed.ncbi.nlm.nih.gov/28257752/

165. Zelenetz, AD, Barrientos, JC, Brown, JR, Coiffier, B, Delgado, J, Egyed, M, et.al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial., Lancet Oncol, 2017. 18 (3)(3): p. 297-311., https://pubmed.ncbi.nlm.nih.gov/28139405/

166. Ghia, Paolo, Pluta, Andrzej, Wach, Malgorzata, Lysak, Daniel, Kozak, Tomas, Simkovic, Martin, et.al. Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND StudyElsevier, Clinical Lymphoma, Myeloma and Leukemia, 2019. 19: p. S280 - S281., https://doi.org/10.1016/j.clml.2019.07.217

167. Jones, JA, Mato, AR, Wierda, WG, Davids, MS, Choi, M, Cheson, BD, et.al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial., Lancet Oncol, 2018. 19 (1): p. 65-75., https://pubmed.ncbi.nlm.nih.gov/29246803/

168. Mato, AR, Roeker, LE, Eyre, TA, Nabhan, C, Lamanna, N, Hill, BT, et.al. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL., Blood Adv, 2019. 3 (10): p. 1568-1573., https://pubmed.ncbi.nlm.nih.gov/31101647/

169. Rogers, KA, Thompson, PA, Allan, JN, Coleman, M, Sharman, JP, Cheson, BD, et.al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia., Haematologica, 2021. 106 (9): p. 2364-2373., https://pubmed.ncbi.nlm.nih.gov/33730844/

170. Mato, AR, Roeker, LE, Jacobs, R, Hill, BT, Lamanna, N, Brander, D, et.al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy., Clin Cancer Res, 2020. 26 (14): p. 3589-3596., https://pubmed.ncbi.nlm.nih.gov/32198151/

171. Woyach, JA, Furman, RR, Liu, TM, Ozer, HG, Zapatka, M, Ruppert, AS, et.al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib., N Engl J Med, 2014. 370 (24): p. 2286-94., https://pubmed.ncbi.nlm.nih.gov/24869598/

172. Mato, AR, Woyach, JA, Brown, JR, Ghia, P, Patel, K, Eyre, TA, et.al. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia., N Engl J Med, 2023. 389 (1): p. 33-44., https://pubmed.ncbi.nlm.nih.gov/37407001/

173. Lim, YS, Yoo, SM, Patil, V, Kim, HW, Kim, HH, Suh, B, et.al. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models., Blood Adv, 2023. 7 (1): p. 92-105., https://pubmed.ncbi.nlm.nih.gov/36269842/

174. Thomalla, D, Beckmann, L, Grimm, C, Oliverio, M, Meder, L, Herling, CD, et.al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies., Blood, 2022. 140 (20): p. 2113-2126., https://pubmed.ncbi.nlm.nih.gov/35704690/

175. Sutton, L., Chevret, S., Tournilhac, O., Divine, M., Leblond, V., Corront, B., et.al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC, Blood, 2011. 117 (23): p. 6109-19., https://www.ncbi.nlm.nih.gov/pubmed/21406717

176. Brion, A., Mahe, B., Kolb, B., Audhuy, B., Colombat, P., Maisonneuve, H., et.al. Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial, Bone Marrow Transplant, 2012. 47 (4): p. 542-8., https://www.ncbi.nlm.nih.gov/pubmed/21725374

177. Magni, M., Di Nicola, M., Patti, C., Scime, R., Mule, A., Rambaldi, A., et.al. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis, Bone Marrow Transplant, 2014. 49 (4): p. 485-91., https://www.ncbi.nlm.nih.gov/pubmed/24442244

178. Dreger, P., Dohner, H., McClanahan, F., Busch, R., Ritgen, M., Greinix, H., et.al. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial, Blood, 2012. 119 (21): p. 4851-9., https://www.ncbi.nlm.nih.gov/pubmed/22490331

179. Michallet, M., Archimbaud, E., Bandini, G., Rowlings, P. A., Deeg, H. J., Gahrton, G., et.al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry, Ann Intern Med, 1996. 124 (3): p. 311-5., https://www.ncbi.nlm.nih.gov/pubmed/8554226

180. Schetelig, J., Thiede, C., Bornhauser, M., Schwerdtfeger, R., Kiehl, M., Beyer, J., et.al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group, J Clin Oncol, 2003. 21 (14): p. 2747-53., https://www.ncbi.nlm.nih.gov/pubmed/12860954

181. Dreger, P., Brand, R., Milligan, D., Corradini, P., Finke, J., Lambertenghi Deliliers, G., et.al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis, Leukemia, 2005. 19 (6): p. 1029-33., https://www.ncbi.nlm.nih.gov/pubmed/15830011

182. Moreno, C., Villamor, N., Colomer, D., Esteve, J., Martino, R., Nomdedeu, J., et.al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia, J Clin Oncol, 2005. 23 (15): p. 3433-8., https://www.ncbi.nlm.nih.gov/pubmed/15809449

183. Pavletic, S. Z., Khouri, I. F., Haagenson, M., King, R. J., Bierman, P. J., Bishop, M. R., et.al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research, J Clin Oncol, 2005. 23 (24): p. 5788-94., https://www.ncbi.nlm.nih.gov/pubmed/16043827

184. Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maris, M., Shizuru, J., Maziarz, R., et.al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning, J Clin Oncol, 2008. 26 (30): p. 4912-20., https://www.ncbi.nlm.nih.gov/pubmed/18794548

185. Toze, C. L., Galal, A., Barnett, M. J., Shepherd, J. D., Conneally, E. A., Hogge, D. E., et.al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease, Bone Marrow Transplant, 2005. 36 (9): p. 825-30., https://www.ncbi.nlm.nih.gov/pubmed/16151430

186. Farina, L., Carniti, C., Dodero, A., Vendramin, A., Raganato, A., Spina, F., et.al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation, Haematologica, 2009. 94 (5): p. 654-62., https://www.ncbi.nlm.nih.gov/pubmed/19377072

187. Hahn, M., et al., Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.Bone Marrow Transplant, 2015. p. 1279-85., https://pubmed.ncbi.nlm.nih.gov/26146810/

188. Krämer, I, Stilgenbauer, S, Dietrich, S, Böttcher, S, Zeis, M, Stadler, M, et.al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial., Blood, 2017. 130 (12): p. 1477-1480., https://pubmed.ncbi.nlm.nih.gov/28716861/

189. Gribben, J. G., Zahrieh, D., Stephans, K., Bartlett-Pandite, L., Alyea, E. P., Fisher, D. C., et.al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia, Blood, 2005. 106 (13): p. 4389-96., https://www.ncbi.nlm.nih.gov/pubmed/16131571

190. Delgado, J., Thomson, K., Russell, N., Ewing, J., Stewart, W., Cook, G., et.al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study, Blood, 2006. 107 (4): p. 1724-30., https://www.ncbi.nlm.nih.gov/pubmed/16239425

191. Schetelig, J., van Biezen, A., Brand, R., Caballero, D., Martino, R., Itala, M., et.al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis, J Clin Oncol, 2008. 26 (31): p. 5094-100., https://www.ncbi.nlm.nih.gov/pubmed/18711173

192. Moreno, C., Villamor, N., Colomer, D., Esteve, J., Gine, E., Muntanola, A., et.al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia, Blood, 2006. 107 (11): p. 4563-9., https://www.ncbi.nlm.nih.gov/pubmed/16449533

193. Ritgen, M., Bottcher, S., Stilgenbauer, S., Bunjes, D., Schubert, J., Cohen, S., et.al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial, Leukemia, 2008. 22 (7): p. 1377-86., https://www.ncbi.nlm.nih.gov/pubmed/18418404

194. Bottcher, S., Ritgen, M., Dreger, P., Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies, Blood Rev, 2011. 25: p. 91-6., https://www.ncbi.nlm.nih.gov/pubmed/21269744

195. Dreger, P., Dohner, H., Ritgen, M., Bottcher, S., Busch, R., Dietrich, S., et.al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia:long-term clinical and MRD results of the GCLLSG CLL3X trial, Blood, 2010. 116 (14): p. 2438-2447., https://www.ncbi.nlm.nih.gov/pubmed/20595516

196. Khouri, I. F., Bassett, R., Poindexter, N., O'Brien, S., Bueso-Ramos, C. E., Hsu, Y., et.al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome, Cancer, 2011. 117 (20): p. 4679-88., https://www.ncbi.nlm.nih.gov/pubmed/21455998

197. Bashey, A., Zhang, X., Sizemore, C. A., Manion, K., Brown, S., Holland, H. K., et.al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation, J Clin Oncol, 2013. 31: p. 1310-6., https://www.ncbi.nlm.nih.gov/pubmed/23423745

198. Michallet, M., Socie, G., Mohty, M., Sobh, M., Bay, J. O., Morisset, S., et.al. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study, Exp Hematol, 2013. 41 (2): p. 127-33., https://www.ncbi.nlm.nih.gov/pubmed/23089183

199. Kim, HT, Shaughnessy, CJ, Rai, SC, Reynolds, C, Ho, VT, Cutler, C, et.al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia., Blood Adv, 2020. 4 (17): p. 4113-4123., https://pubmed.ncbi.nlm.nih.gov/32882002/

200. Roeker, LE, Dreger, P, Brown, JR, Lahoud, OB, Eyre, TA, Brander, DM, et.al. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents., Blood Adv, 2020. 4 (16): p. 3977-3989., https://pubmed.ncbi.nlm.nih.gov/32841336/

201. Tournilhac, O, Le Garff-Tavernier, M, Nguyen Quoc, S, Forcade, E, Chevallier, P, Legrand-Izadifar, F, et.al. Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial., Haematologica, 2021. 106 (7): p. 1867-1875., https://pubmed.ncbi.nlm.nih.gov/32527951/

202. Penack, O, Peczynski, C, Mohty, M, Yakoub-Agha, I, Styczynski, J, Montoto, S, et.al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT., Blood Adv, 2020. 4 (24): p. 6283-6290., https://pubmed.ncbi.nlm.nih.gov/33351121/

203. Kharfan-Dabaja, MA, Moukalled, N, Reljic, T, El-Asmar, J, Kumar, A, Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis., Hematol Oncol Stem Cell Ther, 2018. 11 (2): p. 53-64., https://pubmed.ncbi.nlm.nih.gov/29197550/

204. Pidala, J., Anasetti, C., Jim, H., Quality of life after allogeneic hematopoietic cell transplantation, Blood, 2009. 114 (1): p. 7-19., https://www.ncbi.nlm.nih.gov/pubmed/19336756

205. Aulakh, S, Reljic, T, Yassine, F, Ayala, E, Chavez, JC, Chanan-Khan, A, et.al. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis., Hematol Oncol Stem Cell Ther, 2021. 14 (1): p. 33-40., https://pubmed.ncbi.nlm.nih.gov/32473105/

206. Eyre, TA, Hess, LM, Sugihara, T, He, D, Khanal, M, Pagel, JM, et.al. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study., Leuk Lymphoma, 2023. 64 (5): p. 1005-1016., https://pubmed.ncbi.nlm.nih.gov/36987650/

207. Dreger, P, Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?, Cancer J, 2021. 27 (4): p. 297-305., https://pubmed.ncbi.nlm.nih.gov/34398556/

208. Tsimberidou, A. M., O'Brien, S., Khouri, I., Giles, F. J., Kantarjian, H. M., Champlin, R., et.al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation, J Clin Oncol, 2006. 24 (15): p. 2343-51., https://www.ncbi.nlm.nih.gov/pubmed/16710033

209. Cwynarski, K., van Biezen, A., de Wreede, L., Stilgenbauer, S., Bunjes, D., Metzner, B., et.al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation, J Clin Oncol, 2012. 30 (18): p. 2211-7., https://www.ncbi.nlm.nih.gov/pubmed/22547610

210. van Gelder, M, de Wreede, LC, Bornhäuser, M, Niederwieser, D, Karas, M, Anderson, NS, et.al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation., Bone Marrow Transplant, 2017. 52 (3): p. 372-380., https://pubmed.ncbi.nlm.nih.gov/27941763/

211. Schetelig, J, Chevallier, P, van Gelder, M, Hoek, J, Hermine, O, Chakraverty, R, et.al. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party., Bone Marrow Transplant, 2021. 56 (3): p. 605-613., https://pubmed.ncbi.nlm.nih.gov/33004942/

212. Dreger, P., Brand, R., Hansz, J., Milligan, D., Corradini, P., Finke, J., et.al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning, Leukemia, 2003. 17 (5): p. 841-8., https://www.ncbi.nlm.nih.gov/pubmed/12750695

213. Sorror, M. L., Maris, M. B., Sandmaier, B. M., Storer, B. E., Stuart, M. J., Hegenbart, U., et.al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia, J Clin Oncol, 2005. 23 (16): p. 3819-29., https://www.ncbi.nlm.nih.gov/pubmed/15809448

214. Brown, J. R., Kim, H. T., Armand, P., Cutler, C., Fisher, D. C., Ho, V., et.al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome, Leukemia, 2013. 27 (2): p. 362-9., https://www.ncbi.nlm.nih.gov/pubmed/22955330

215. Dreger, P., Schnaiter, A., Zenz, T., Bottcher, S., Rossi, M., Paschka, P., et.al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial, Blood, 2013., https://www.ncbi.nlm.nih.gov/pubmed/23435461

216. Kater, AP, Wu, JQ, Kipps, T, Eichhorst, B, Hillmen, P, D'Rozario, J, et.al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study., J Clin Oncol, 2020. 38 (34): p. 4042-4054., https://pubmed.ncbi.nlm.nih.gov/32986498/

217. Schetelig, J, de Wreede, LC, Andersen, NS, Moreno, C, van Gelder, M, Vitek, A, et.al. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)., Br J Haematol, 2017. 178 (4): p. 521-533., https://pubmed.ncbi.nlm.nih.gov/28589551/

218. Michallet, M., Sobh, M., Milligan, D., Morisset, S., Niederwieser, D., Koza, V., et.al. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry, Leukemia, 2010. 24 (10): p. 1725-31., https://www.ncbi.nlm.nih.gov/pubmed/20703257

219. Fleischhauer, K, Tran, TH, Meisel, R, Mytilineos, J, Dreger, P, Kröger, N, Donor Selection for Allogeneic Hematopoietic Cell Transplantation., Dtsch Arztebl Int, 2023. 120 (15): p. 261-268., https://pubmed.ncbi.nlm.nih.gov/36949660/

220. Frey, NV, Gill, S, Hexner, EO, Schuster, S, Nasta, S, Loren, A, et.al. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia., J Clin Oncol, 2020. 38 (25): p. 2862-2871., https://pubmed.ncbi.nlm.nih.gov/32298202/

221. Siddiqi, T, Maloney, DG, Kenderian, SS, Brander, DM, Dorritie, K, Soumerai, J, et.al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study., Lancet, 2023. 402 (10402): p. 641-654., https://pubmed.ncbi.nlm.nih.gov/37295445/

222. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., et.al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition., International Agency for Research on Cancer (IARC) Lyon, 2008., https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017

223. Tsimberidou, A. M., Keating, M. J., Richter syndrome: biology, incidence, and therapeutic strategies, Cancer, 2005. 103 (2): p. 216-28., https://www.ncbi.nlm.nih.gov/pubmed/15578683

224. Tsimberidou, A. M., Keating, M. J., Richter's transformation in chronic lymphocytic leukemia, Semin Oncol, 2006. 33 (2): p. 250-6., https://www.ncbi.nlm.nih.gov/pubmed/16616072

225. Yee, K. W., O'Brien, S. M., Giles, F. J., Richter's syndrome: biology and therapy, Cancer J, 2005. 11 (3): p. 161-74., https://www.ncbi.nlm.nih.gov/pubmed/16053658

226. Vitale, C., Ferrajoli, A., Richter Syndrome in Chronic Lymphocytic Leukemia, Curr Hematol Malig Rep, 2016. 11 (1): p. 43-51., https://www.ncbi.nlm.nih.gov/pubmed/26830086

227. Jamroziak, K., Tadmor, T., Robak, T., Polliack, A., Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy, Leuk Lymphoma, 2015. 56 (7): p. 1949-58., https://www.ncbi.nlm.nih.gov/pubmed/25356923

228. Hossfeld, D. K., E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Annals of Oncology, 2002. 13: p. 490-491., http://annonc.oxfordjournals.org/content/13/3/490.2.short

229. Rossi, D., Richter's syndrome: Novel and promising therapeutic alternatives, Best Pract Res Clin Haematol, 2016. 29 (1): p. 30-39., https://www.ncbi.nlm.nih.gov/pubmed/27742070

230. Al-Sawaf, O, Robrecht, S, Bahlo, J, Fink, AM, Cramer, P, V Tresckow, J, et.al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials., Leukemia, 2021. 35 (1): p. 169-176., https://pubmed.ncbi.nlm.nih.gov/32203141/

231. Bockorny, B., Codreanu, I., Dasanu, C. A., Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature, Br J Haematol, 2012. 156: p. 50-66., https://www.ncbi.nlm.nih.gov/pubmed/22017478

232. Brecher, M., Banks, P. M., Hodgkin's disease variant of Richter's syndrome. Report of eight cases, Am J Clin Pathol, 1990. 93: p. 333-9., https://www.ncbi.nlm.nih.gov/pubmed/1689938

233. Mao, Z., Quintanilla-Martinez, L., Raffeld, M., Richter, M., Krugmann, J., Burek, C., et.al. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution, Am J Surg Pathol, 2007. 31 (10): p. 1605-14., https://www.ncbi.nlm.nih.gov/pubmed/17895764

234. Ohno, T., Smir, B. N., Weisenburger, D. D., Gascoyne, R. D., Hinrichs, S. D., Chan, W. C., Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with "Hodgkin's transformation", Blood, 1998. 91 (5): p. 1757-61., https://www.ncbi.nlm.nih.gov/pubmed/9473243

235. Richter, M. N., Generalized Reticular Cell Sarcoma of Lymph Nodes Associated with Lymphatic Leukemia, Am J Pathol, 1928. 4 (4): p. 285-292 7., https://www.ncbi.nlm.nih.gov/pubmed/19969796

236. Lortholary, P., Boiron, M., Ripault, P., Levy, J. P., Manus, A., Bernard, J., [Chronic Lymphoid Leukemia Secondarily Associated with a Malignant Reticulopathy: Richter's Syndrome], Nouv Rev Fr Hematol, 1964. 4: p. 621-44., https://www.ncbi.nlm.nih.gov/pubmed/14199493

237. Stein, H., Kaiserling, E., Lennert, K., Evidence for B-cell origin of reticulum cell sarcoma, Virchows Arch A Pathol Anat Histol, 1974. 364 (1): p. 51-67., https://www.ncbi.nlm.nih.gov/pubmed/4374798

238. Parikh, S. A., Rabe, K. G., Call, T. G., Zent, C. S., Habermann, T. M., Ding, W., et.al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients, Br J Haematol, 2013. 162 (6): p. 774-82., https://www.ncbi.nlm.nih.gov/pubmed/23841899

239. Rossi, D., Cerri, M., Capello, D., Deambrogi, C., Rossi, F. M., Zucchetto, A., et.al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome, Br J Haematol, 2008. 142 (2): p. 202-15., https://www.ncbi.nlm.nih.gov/pubmed/18492108

240. Ott, M. M., Ott, G., Roblick, U., Linke, B., Kneba, M., de Leon, F., et.al. Localized gastric non-Hodgkin's lymphoma of high-grade malignancy in patients with pre-existing chronic lymphocytic leukemia or immunocytoma, Leukemia, 1995. 9 (4): p. 609-14., https://www.ncbi.nlm.nih.gov/pubmed/7723393

241. Omoti, C. E., Omoti, A. E., Richter syndrome: a review of clinical, ocular, neurological and other manifestations, Br J Haematol, 2008. 142 (5): p. 709-16., https://www.ncbi.nlm.nih.gov/pubmed/18492119

242. Mato, AR, Wierda, WG, Davids, MS, Cheson, BD, Coutre, SE, Choi, M, et.al. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy., Haematologica, 2019. 104 (11): p. 2258-2264., https://pubmed.ncbi.nlm.nih.gov/30923097/

243. Bruzzi, J. F., Macapinlac, H., Tsimberidou, A. M., Truong, M. T., Keating, M. J., Marom, E. M., et.al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT, J Nucl Med, 2006. 47 (8): p. 1267-73., https://www.ncbi.nlm.nih.gov/pubmed/16883004

244. Mauro, F. R., Chauvie, S., Paoloni, F., Biggi, A., Cimino, G., Rago, A., et.al. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease, Leukemia, 2015. 29 (6): p. 1360-5., https://www.ncbi.nlm.nih.gov/pubmed/25650091

245. Mato, Anthony R., Wierda, William G, Davids, Matthew S., Cheson, Bruce D., Coutre, Steven, Choi, Michael, et.al. Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy, 2017. 130: p. 834., https://www.sciencedirect.com/science/article/pii/S0006497119813502

246. Chigrinova, E., Rinaldi, A., Kwee, I., Rossi, D., Rancoita, P. M., Strefford, J. C., et.al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome, Blood, 2013. 122 (15): p. 2673-82., https://www.ncbi.nlm.nih.gov/pubmed/24004666

247. Scandurra, M., Rossi, D., Deambrogi, C., Rancoita, P. M., Chigrinova, E., Mian, M., et.al. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas, Hematol Oncol, 2010. 28 (2): p. 62-7., https://www.ncbi.nlm.nih.gov/pubmed/20014148

248. Fabbri, G., Khiabanian, H., Holmes, A. B., Wang, J., Messina, M., Mullighan, C. G., et.al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome, J Exp Med, 2013. 210 (11): p. 2273-88., https://www.ncbi.nlm.nih.gov/pubmed/24127483

249. Rossi, D., Spina, V., Deambrogi, C., Rasi, S., Laurenti, L., Stamatopoulos, K., et.al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation, Blood, 2011. 117 (12): p. 3391-401., https://www.ncbi.nlm.nih.gov/pubmed/21266718

250. Momose, H., Jaffe, E. S., Shin, S. S., Chen, Y. Y., Weiss, L. M., Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin's disease. Mediation by Epstein-Barr virus, Am J Surg Pathol, 1992. 16 (9): p. 859-67., https://www.ncbi.nlm.nih.gov/pubmed/1384376

251. Wierda, WG, Brown, J, Abramson, JS, Awan, F, Bilgrami, SF, Bociek, G, et.al. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022., J Natl Compr Canc Netw, 2022. 20 (6): p. 622-634., https://pubmed.ncbi.nlm.nih.gov/35714675/

252. Karlsson, C., Norin, S., Kimby, E., Sander, B., Porwit Macdonald, A., Nilsson, B., et.al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation, Leukemia, 2006. 20 (12): p. 2204-7., https://www.ncbi.nlm.nih.gov/pubmed/17051245

253. Gotze, K. S., Hoffmann, D., Schatzl, H. M., Peschel, C., Fend, F., Decker, T., Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells, Haematologica, 2007. 92 (9): p. 1282-3., https://www.ncbi.nlm.nih.gov/pubmed/17768130

254. Jain, P., Benjamini, O., Konoplev, S., Mohamed, M. S., Romo, C. G., Estrov, Z., Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia, Leuk Lymphoma, 2013. 54 (11): p. 2540-2., https://www.ncbi.nlm.nih.gov/pubmed/23387894

255. Parikh, S. A., Habermann, T. M., Chaffee, K. G., Call, T. G., Ding, W., Leis, J. F., et.al. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma, Am J Hematol, 2015. 90 (4): p. 334-8., https://www.ncbi.nlm.nih.gov/pubmed/25581025

256. Parikh, S. A., Shanafelt, T. D., Risk factors for Richter syndrome in chronic lymphocytic leukemia, Curr Hematol Malig Rep, 2014. 9 (3): p. 294-9., https://www.ncbi.nlm.nih.gov/pubmed/25218362

257. Rossi, D., Spina, V., Cerri, M., Rasi, S., Deambrogi, C., De Paoli, L., et.al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome, Clin Cancer Res, 2009. 15 (13): p. 4415-22., https://www.ncbi.nlm.nih.gov/pubmed/19509140

258. Parikh, S. A., Kay, N. E., Shanafelt, T. D., How we treat Richter syndrome, Blood, 2014. 123 (11): p. 1647-57., https://www.ncbi.nlm.nih.gov/pubmed/24421328

259. Hamblin, T. J., Richter's syndrome--the downside of fludarabine?, Leuk Res, 2005. 29 (10): p. 1103-4., https://www.ncbi.nlm.nih.gov/pubmed/16111529

260. Rossi, D., Richter syndrome and fludarabine: a controversial relationship, Leuk Lymphoma, 2013. 54 (2): p. 213-4., https://www.ncbi.nlm.nih.gov/pubmed/22897730

261. Rossi, D., Rasi, S., Spina, V., Fangazio, M., Monti, S., Greco, M., et.al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome, Br J Haematol, 2012. 158 (3): p. 426-9., https://www.ncbi.nlm.nih.gov/pubmed/22571487

262. Villamor, N., Conde, L., Martinez-Trillos, A., Cazorla, M., Navarro, A., Bea, S., et.al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome, Leukemia, 2013. 27 (5): p. 1100-6., https://www.ncbi.nlm.nih.gov/pubmed/23295735

263. Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., et.al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, N Engl J Med, 2013. 369 (1): p. 32-42., https://www.ncbi.nlm.nih.gov/pubmed/23782158

264. O'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., et.al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial, Lancet Oncol, 2014. 15 (1): p. 48-58., https://www.ncbi.nlm.nih.gov/pubmed/24332241

265. Jain, P., Keating, M., Wierda, W., Estrov, Z., Ferrajoli, A., Jain, N., et.al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib, Blood, 2015. 125 (13): p. 2062-7., https://www.ncbi.nlm.nih.gov/pubmed/25573991

266. Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., et.al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia, JAMA Oncol, 2015. 1 (1): p. 80-7., https://www.ncbi.nlm.nih.gov/pubmed/26182309

267. Langerbeins, P., Busch, R., Anheier, N., Durig, J., Bergmann, M., Goebeler, M. E., et.al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation, Am J Hematol, 2014. 89 (12): p. E239-43., https://www.ncbi.nlm.nih.gov/pubmed/25196783

268. Tsimberidou, A. M., Kantarjian, H. M., Cortes, J., Thomas, D. A., Faderl, S., Garcia-Manero, G., et.al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia, Cancer, 2003. 97 (7): p. 1711-20., https://www.ncbi.nlm.nih.gov/pubmed/12655528

269. Tsimberidou, A. M., Wierda, W. G., Plunkett, W., Kurzrock, R., O'Brien, S., Wen, S., et.al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia, J Clin Oncol, 2008. 26 (2): p. 196-203., https://www.ncbi.nlm.nih.gov/pubmed/18182662

270. Tsimberidou, A. M., Wierda, W. G., Wen, S., Plunkett, W., O'Brien, S., Kipps, T. J., et.al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome, Clin Lymphoma Myeloma Leuk, 2013. 13 (5): p. 568-74., https://www.ncbi.nlm.nih.gov/pubmed/23810245

271. Dabaja, B. S., O'Brien, S. M., Kantarjian, H. M., Cortes, J. E., Thomas, D. A., Albitar, M., et.al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome, Leuk Lymphoma, 2001. 42 (3): p. 329-37., https://www.ncbi.nlm.nih.gov/pubmed/11699397

272. Tadmor, T., Shvidel, L., Bairey, O., Goldschmidt, N., Ruchlemer, R., Fineman, R., et.al. Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group, Am J Hematol, 2014. 89 (11): p. E218-22., https://www.ncbi.nlm.nih.gov/pubmed/25110869

273. Herrera, AF, Ahn, KW, Litovich, C, Chen, Y, Assal, A, Bashir, Q, et.al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome., Blood Adv, 2021. 5 (18): p. 3528-3539., https://pubmed.ncbi.nlm.nih.gov/34496026/

274. Davids, MS, Rogers, KA, Tyekucheva, S, Wang, Z, Pazienza, S, Renner, SK, et.al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome., Blood, 2022. 139 (5): p. 686-689., https://pubmed.ncbi.nlm.nih.gov/34788401/

275. Kittai, AS, Bond, DA, William, B, Saad, A, Penza, S, Efebera, Y, et.al. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome., Blood Adv, 2020. 4 (19): p. 4648-4652., https://pubmed.ncbi.nlm.nih.gov/33002129/

276. Benjamini, Ohad, Shimoni, Avichai, Besser, Michal, Shem-Tov, Noga, Danylesko, Ivetta, Yerushalmi, Ronit, et.al. Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia, 2020. 136: p. 40., https://www.sciencedirect.com/science/article/pii/S0006497118697472

277. Younes, A, Brody, J, Carpio, C, Lopez-Guillermo, A, Ben-Yehuda, D, Ferhanoglu, B, et.al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study., Lancet Haematol, 2019. 6 (2): p. e67-e78., https://pubmed.ncbi.nlm.nih.gov/30642819/

278. Tsang, M., Shanafelt, T. D., Call, T. G., Ding, W., Chanan-Khan, A., Leis, J. F., et.al. The efficacy of ibrutinib in the treatment of Richter syndrome, Blood, 2015. 125: p. 1676-8., https://www.ncbi.nlm.nih.gov/pubmed/25745187

279. Eyre, TA, Riches, JC, Patten, PEM, Walewska, R, Marr, H, Follows, G, et.al. Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper., Br J Haematol, 2022. 196 (4): p. 864-870., https://pubmed.ncbi.nlm.nih.gov/34607388/

280. Jain, N, Senapati, J, Thakral, B, Ferrajoli, A, Thompson, P, Burger, J, et.al. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL., Blood Adv, 2023. 7 (10): p. 1958-1966., https://pubmed.ncbi.nlm.nih.gov/36287248/

281. Davids, MS, Roberts, AW, Seymour, JF, Pagel, JM, Kahl, BS, Wierda, WG, et.al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma., J Clin Oncol, 2017. 35 (8): p. 826-833., https://pubmed.ncbi.nlm.nih.gov/28095146/

282. Morschhauser, F, Feugier, P, Flinn, IW, Gasiorowski, R, Greil, R, Illés, Á, et.al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma., Blood, 2021. 137 (5): p. 600-609., https://pubmed.ncbi.nlm.nih.gov/33538797/

283. Frustaci, A. M., Tedeschi, A., Zinzani, P. L., Pietrasanta, D., Coscia, M., Zenz, T., et.al. MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSISJohn Wiley & Sons, Ltd, Hematological Oncology, 2021. 39(S2):, https://doi.org/10.1002/hon.40_2880

284. Al-Sawaf, O, Ligtvoet, R, Robrecht, S, Stumpf, J, Fink, AM, Tausch, E, et.al. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial., Nat Med, 2024. 30 (1): p. 240-248., https://pubmed.ncbi.nlm.nih.gov/38071379/

285. Guieze, Romain, Ysebaert, Loic, Roos-Weil, Damien, Fornecker, Luc-Matthieu, Ferrant, Emmanuelle, Molina, Lysiane, et.al. Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group, 2022. 140(Supplement 1): p. 6631 - 6632., https://doi.org/10.1182/blood-2022-159695

286. Kater, Arnon P., Ye, J Christine, Sandoval-Sus, Jose, Bellido, Mar, Christensen, Jacob Haaber, Mato, Anthony R., et.al. Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1), 2022. 140(Supplement 1): p. 850 - 851., https://doi.org/10.1182/blood-2022-158298

287. Carlo-Stella, C., Hutchings, M., Offner, F., Mulvihill, E., Relf, J., Byrne, B., et.al. GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATIONJohn Wiley & Sons, Ltd, Hematological Oncology, 2023. 41(S2): p. 63 - 65., https://doi.org/10.1002/hon.3163_28

288. Hamblin, TJ, Autoimmune complications of chronic lymphocytic leukemia., Semin Oncol, 2006. 33 (2): p. 230-9., https://pubmed.ncbi.nlm.nih.gov/16616070/

289. Dearden, C, Disease-specific complications of chronic lymphocytic leukemia., Hematology Am Soc Hematol Educ Program, 2008. p. 450-6., https://pubmed.ncbi.nlm.nih.gov/19074125/

290. Demir, C, Ekinci, Ö, Clinical and serological autoimmune complications in chronic lymphocytic leukemia., Wien Klin Wochenschr, 2017. 129 (15-16): p. 552-557., https://pubmed.ncbi.nlm.nih.gov/28477093/

291. Krol, AD, le Cessie, S, Snijder, S, Kluin-Nelemans, JC, Kluin, PM, Noordijk, EM, Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry., Ann Oncol, 2003. 14 (1): p. 131-9., https://pubmed.ncbi.nlm.nih.gov/12488305/

292. Groves, FD, Linet, MS, Travis, LB, Devesa, SS, Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995., J Natl Cancer Inst, 2000. 92 (15): p. 1240-51., https://pubmed.ncbi.nlm.nih.gov/10922409/

293. Cramer, P, Bahlo, J, Eichhorst, B, Fischer, K, Hallek, M, Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual., Leuk Res, 2014. 38 (3): p. 284-5., https://pubmed.ncbi.nlm.nih.gov/24412156/

294. Ratterman, M, Kruczek, K, Sulo, S, Shanafelt, TD, Kay, NE, Nabhan, C, Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012., Leuk Res, 2014. 38 (3): p. 299-303., https://pubmed.ncbi.nlm.nih.gov/24064196/

295. Greenwood, R, Barker, DJ, Tring, FC, Parapia, L, Reid, M, Scott, CS, et.al. Clinical and immunohistological characterization of cutaneous lesions in chronic lymphocytic leukaemia., Br J Dermatol, 1985. 113 (4): p. 447-53., https://pubmed.ncbi.nlm.nih.gov/3877521/

296. Gordon, MJ, Ferrajoli, A, Unusual complications in the management of chronic lymphocytic leukemia., Am J Hematol, 2022. 97 (Suppl 2): p. S26-S34., https://pubmed.ncbi.nlm.nih.gov/35491515/

297. Robak, E, Robak, T, Skin lesions in chronic lymphocytic leukemia., Leuk Lymphoma, 2007. 48 (5): p. 855-65., https://pubmed.ncbi.nlm.nih.gov/17487727/

298. Strati, P, Uhm, JH, Kaufmann, TJ, Nabhan, C, Parikh, SA, Hanson, CA, et.al. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia., Haematologica, 2016. 101 (4): p. 458-65., https://pubmed.ncbi.nlm.nih.gov/26819053/

299. Wanquet, A, Birsen, R, Bonnet, C, Boubaya, M, Choquet, S, Dupuis, J, et.al. Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients., Br J Haematol, 2017. 176 (1): p. 37-49., https://pubmed.ncbi.nlm.nih.gov/27858991/

300. Strati, P, Nasr, SH, Leung, N, Hanson, CA, Chaffee, KG, Schwager, SM, et.al. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience., Haematologica, 2015. 100 (9): p. 1180-8., https://pubmed.ncbi.nlm.nih.gov/26088927/

301. Chai, KL, Wong, J, Weinkove, R, Keegan, A, Crispin, P, Stanworth, S, et.al. Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis., Blood Adv, 2023. 7 (1): p. 20-31., https://pubmed.ncbi.nlm.nih.gov/35882473/

302. Walz-Mattmüller, R, Horny, HP, Ruck, P, Kaiserling, E, Incidence and pattern of liver involvement in haematological malignancies., Pathol Res Pract, 1998. 194 (11): p. 781-9., https://pubmed.ncbi.nlm.nih.gov/9842637/

303. Robak, T, Kasprzak, JD, Jesionek-Kupnicka, D, Chudobiński, C, Robak, P, Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma., J Clin Med, 2022. 11 (23):, https://pubmed.ncbi.nlm.nih.gov/36498556/

304. Kipps, T. J., Carson, D. A., Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases, Blood, 1993. 81 (10): p. 2475-87., https://www.ncbi.nlm.nih.gov/pubmed/8490163

305. Rebmann, V., Nuckel, H., Duhrsen, U., Grosse-Wilde, H., HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications, Semin Cancer Biol, 2007. 17 (6): p. 430-5., https://www.ncbi.nlm.nih.gov/pubmed/17683947

306. Maura, F, Visco, C, Falisi, E, Reda, G, Fabris, S, Agnelli, L, et.al. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia., Am J Hematol, 2013. 88 (1): p. 32-6., https://pubmed.ncbi.nlm.nih.gov/23115077/

307. Moreno, C., Hodgson, K., Ferrer, G., Elena, M., Filella, X., Pereira, A., et.al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance, Blood, 2010. 116 (23): p. 4771-6., https://www.ncbi.nlm.nih.gov/pubmed/20736453

308. Zent, C. S., Ding, W., Schwager, S. M., Reinalda, M. S., Hoyer, J. D., Jelinek, D. F., et.al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma, Br J Haematol, 2008. 141 (5): p. 615-21., https://www.ncbi.nlm.nih.gov/pubmed/18373706

309. Visco, C., Giaretta, I., Ruggeri, M., Madeo, D., Tosetto, A., Rodeghiero, F., Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia, Leukemia, 2007. 21 (5): p. 1092-3., https://www.ncbi.nlm.nih.gov/pubmed/17301811

310. Myint, H., Copplestone, J. A., Orchard, J., Craig, V., Curtis, D., Prentice, A. G., et.al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia, Br J Haematol, 1995. 91 (2): p. 341-4., https://www.ncbi.nlm.nih.gov/pubmed/8547072

311. Ding, W., Zent, C. S., Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/ small lymphocytic lymphoma, Clin Adv Hematol Oncol, 2007. 5 (4): p. 257-61., https://www.ncbi.nlm.nih.gov/pubmed/17607284

312. Rogers, K. A., Woyach, J. A., Secondary autoimmune cytopenias in chronic lymphocytic leukemia, Semin Oncol, 2016. 43 (2): p. 300-10., https://www.ncbi.nlm.nih.gov/pubmed/27040709

313. Vitale, C, Montalbano, MC, Salvetti, C, Boccellato, E, Griggio, V, Boccadoro, M, et.al. Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs., Cancers (Basel), 2020. 12 (2):, https://pubmed.ncbi.nlm.nih.gov/31979293/

314. Federici, AB, Rand, JH, Bucciarelli, P, Budde, U, van Genderen, PJ, Mohri, H, et.al. Acquired von Willebrand syndrome: data from an international registry., Thromb Haemost, 2000. 84 (2): p. 345-9., https://pubmed.ncbi.nlm.nih.gov/10959711/

315. D'Arena, G., Laurenti, L., Capalbo, S., D'Arco, A. M., De Filippi, R., Marcacci, G., et.al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia, American Journal of Hematology, 2006. 81 (8): p. 598-602., https://www.ncbi.nlm.nih.gov/pubmed/16823816

316. Jäger, U, Barcellini, W, Broome, CM, Gertz, MA, Hill, A, Hill, QA, et.al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting., Blood Rev, 2020. 41: p. 100648., https://pubmed.ncbi.nlm.nih.gov/31839434/

317. O'Brien, S., del Giglio, A., Keating, M., Advances in the biology and treatment of B-cell chronic lymphocytic leukemia, Blood, 1995. 85 (2): p. 307-18., https://www.ncbi.nlm.nih.gov/pubmed/7811987

318. Meyer, O, Stahl, D, Beckhove, P, Huhn, D, Salama, A, Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type., Br J Haematol, 1997. 98 (4): p. 860-2., https://pubmed.ncbi.nlm.nih.gov/9326179/

319. Wei, Y, Ji, XB, Wang, YW, Wang, JX, Yang, EQ, Wang, ZC, et.al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial., Blood, 2016. 127 (3): p. 296-302; quiz 370., https://pubmed.ncbi.nlm.nih.gov/26480931/

320. Rogers, KA, Ruppert, AS, Bingman, A, Andritsos, LA, Awan, FT, Blum, KA, et.al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia., Leukemia, 2016. 30 (2): p. 346-50., https://pubmed.ncbi.nlm.nih.gov/26442611/

321. Quinquenel, A, Godet, S, Dartigeas, C, Ysebaert, L, Dupuis, J, Ohanyan, H, et.al. Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group., Am J Hematol, 2019. 94 (7): p. E183-E185., https://pubmed.ncbi.nlm.nih.gov/30945328/

322. Hampel, PJ, Larson, MC, Kabat, B, Call, TG, Ding, W, Kenderian, SS, et.al. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre., Br J Haematol, 2018. 183 (3): p. 421-427., https://pubmed.ncbi.nlm.nih.gov/30117139/

323. Gordon, MJ, Maldonado, E, Danilov, AV, Refractory Autoimmune Cytopenias Treated With Venetoclax., Hemasphere, 2019. 3 (3): p. e202., https://pubmed.ncbi.nlm.nih.gov/31723832/

324. Galindo-Navarro, P, Delgado-García, A, Rodríguez-Gil, MA, Puerta-Puerta, JM, Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain., Haematologica, 2023. 108 (8): p. 2261-2264., https://pubmed.ncbi.nlm.nih.gov/36861400/

325. GBA (Gemeinsamer Bundesausschuss), Nutzenbewertungsverfahren zum Wirkstoff Sutimlimab (Kälteagglutinin-Krankheit), 2023., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/912/

326. Gurnari, C, Maciejewski, JP, How I manage acquired pure red cell aplasia in adults., Blood, 2021. 137 (15): p. 2001-2009., https://pubmed.ncbi.nlm.nih.gov/33657207/

327. Sawada, K., Fujishima, N., Hirokawa, M., Acquired pure red cell aplasia: updated review of treatment, Br J Haematol, 2008. 142 (4): p. 505-14., https://www.ncbi.nlm.nih.gov/pubmed/18510682

328. D'Arena, G, Cascavilla, N, Chronic lymphocytic leukemia-associated pure red cell aplasia., Int J Immunopathol Pharmacol, 2009. 22 (2): p. 279-86., https://pubmed.ncbi.nlm.nih.gov/19505381/

329. Classen, AY, Henze, L, von Lilienfeld-Toal, M, Maschmeyer, G, Sandherr, M, Graeff, LD, et.al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)., Ann Hematol, 2021. 100 (6): p. 1603-1620., https://pubmed.ncbi.nlm.nih.gov/33846857/

330. Henze, L, Buhl, C, Sandherr, M, Cornely, OA, Heinz, WJ, Khodamoradi, Y, et.al. Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus., Ann Hematol, 2022. 101 (3): p. 491-511., https://pubmed.ncbi.nlm.nih.gov/34994811/

331. Sandherr, M, Hentrich, M, von Lilienfeld-Toal, M, Massenkeil, G, Neumann, S, Penack, O, et.al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)., Ann Hematol, 2015. 94 (9): p. 1441-50., https://pubmed.ncbi.nlm.nih.gov/26193852/

332. Stemler, J, Mellinghoff, SC, Khodamoradi, Y, Sprute, R, Classen, AY, Zapke, SE, et.al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)., J Antimicrob Chemother, 2023. 78 (8): p. 1813-1826., https://pubmed.ncbi.nlm.nih.gov/37311136/

333. Freeman, JA, Crassini, KR, Best, OG, Forsyth, CJ, Mackinlay, NJ, Han, P, et.al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia., Leuk Lymphoma, 2013. 54 (1): p. 99-104., https://pubmed.ncbi.nlm.nih.gov/22738394/

334. Molica, S, Musto, P, Chiurazzi, F, Specchia, G, Brugiatelli, M, Cicoira, L, et.al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study., Haematologica, 1996. 81 (2): p. 121-6., https://pubmed.ncbi.nlm.nih.gov/8641639/

335. Gale, RP, Chapel, HM, Bunch, C, Rai, KR, Foon, K, Courter, SG et.al., Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, N Engl J Med, 1988. 319: p. 902-7., https://www.ncbi.nlm.nih.gov/pubmed/2901668

336. Sim, B, Ng, JY, Teh, BW, Talaulikar, D, Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule., Leuk Lymphoma, 2023. 64 (1): p. 18-29., https://pubmed.ncbi.nlm.nih.gov/36218218/

337. Vacca, A, Melaccio, A, Sportelli, A, Solimando, AG, Dammacco, F, Ria, R, Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial., Clin Immunol, 2018. 191: p. 110-115., https://pubmed.ncbi.nlm.nih.gov/29191714/

338. Cornely, Oliver, Mato, Anthony, Robak, Tadeusz, Mellinghoff, Sibylle, Lavrova, Tatiana, The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIG) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia- Study Design, 2020. 136: p. 20 - 21., https://www.sciencedirect.com/science/article/pii/S000649711870534X

339. Maschmeyer, G, De Greef, J, Mellinghoff, SC, Nosari, A, Thiebaut-Bertrand, A, Bergeron, A, et.al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)., Leukemia, 2019. 33 (4): p. 844-862., https://pubmed.ncbi.nlm.nih.gov/30700842/

340. Mikulska, M, Lanini, S, Gudiol, C, Drgona, L, Ippolito, G, Fernández-Ruiz, M, et.al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)., Clin Microbiol Infect, 2018. 24 (Suppl 2): p. S71-S82., https://pubmed.ncbi.nlm.nih.gov/29447988/

341. Satterthwaite, AB, Witte, ON, The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective., Immunol Rev, 2000. 175: p. 120-7., https://pubmed.ncbi.nlm.nih.gov/10933597/

342. BRUTON, OC, Agammaglobulinemia., Pediatrics, 1952. 9 (6): p. 722-8., https://pubmed.ncbi.nlm.nih.gov/14929630/

343. Wang, ML, Rule, S, Martin, P, Goy, A, Auer, R, Kahl, BS, et.al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma., N Engl J Med, 2013. 369 (6): p. 507-16., https://pubmed.ncbi.nlm.nih.gov/23782157/

344. Okamoto, K, Proia, LA, Demarais, PL, Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib., Case Rep Infect Dis, 2016. 2016: p. 4642831., https://pubmed.ncbi.nlm.nih.gov/27703818/

345. Sun, K, Kasparian, S, Iyer, S, Pingali, SR, Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib., Ecancermedicalscience, 2018. 12: p. 836., https://pubmed.ncbi.nlm.nih.gov/29910833/

346. Messina, JA, Maziarz, EK, Spec, A, Kontoyiannis, DP, Perfect, JR, Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib., Open Forum Infect Dis, 2017. 4 (1): p. ofw261., https://pubmed.ncbi.nlm.nih.gov/28480254/

347. Wang, SY, Ebert, T, Jaekel, N, Schubert, S, Niederwieser, D, Al-Ali, HK, Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia., Ann Hematol, 2015. 94 (8): p. 1419-20., https://pubmed.ncbi.nlm.nih.gov/25903044/

348. Cavallari, M, Ciccone, M, Falzoni, S, Cavazzini, F, Formigaro, L, Di Virgilio, F, et.al. "Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia"., Leuk Res Rep, 2017. 7 (): p. 11-13., https://pubmed.ncbi.nlm.nih.gov/28180067/

349. Hammond, SP, Chen, K, Pandit, A, Davids, MS, Issa, NC, Marty, FM, Risk of hepatitis B virus reactivation in patients treated with ibrutinib., Blood, 2018. 131 (17): p. 1987-1989., https://pubmed.ncbi.nlm.nih.gov/29490923/

350. Herishanu, Y, Katchman, H, Polliack, A, Severe hepatitis B virus reactivation related to ibrutinib monotherapy., Ann Hematol, 2017. 96 (4): p. 689-690., https://pubmed.ncbi.nlm.nih.gov/28058492/

351. Ghez, D, Calleja, A, Protin, C, Baron, M, Ledoux, MP, Damaj, G, et.al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib., Blood, 2018. 131 (17): p. 1955-1959., https://pubmed.ncbi.nlm.nih.gov/29437588/

352. Fürstenau, M, Simon, F, Cornely, OA, Hicketier, T, Eichhorst, B, Hallek, M, et.al. Invasive Aspergillosis in Patients Treated With Ibrutinib., Hemasphere, 2020. 4 (2): p. e309., https://pubmed.ncbi.nlm.nih.gov/32309779/

353. Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., et.al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia, N Engl J Med, 2015., https://www.ncbi.nlm.nih.gov/pubmed/26639348

354. Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., et.al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study, Lancet Oncol, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27178240

355. Bonuomo, V, Ferrarini, I, Dell'Eva, M, Sbisà, E, Krampera, M, Visco, C, COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review., World J Virol, 2021. 10 (6): p. 312-325., https://pubmed.ncbi.nlm.nih.gov/34909405/

356. Infante, MS, Salmanton-García, J, Fernández-Cruz, A, Marchesi, F, Jaksic, O, Weinbergerová, B, et.al. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)., Front Oncol, 2022. 12: p. 992137., https://pubmed.ncbi.nlm.nih.gov/36276116/

357. Blennow, O, Salmanton-García, J, Nowak, P, Itri, F, Van Doesum, J, López-García, A, et.al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report., Am J Hematol, 2022. 97 (8): p. E312-E317., https://pubmed.ncbi.nlm.nih.gov/35702878/

358. RKI - Fachgruppe COVRIIN, COVID-19 Risikomanagement im intensivmedizinischen Netzwerk., 2021., https://www.rki.de/DE/Themen/Infektionskrankheiten/Biologische-Gefahren/COVRIIN/Ueber-die-Fachgruppe-COVRIIN/FG_COVRIIN.html

359. Rieger, CT, Liss, B, Mellinghoff, S, Buchheidt, D, Cornely, OA, Egerer, G, et.al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)., Ann Oncol, 2018. 29 (6): p. 1354-1365., https://pubmed.ncbi.nlm.nih.gov/29688266/

360. Giesen, N, Busch, E, Schalk, E, Beutel, G, Rüthrich, MM, Hentrich, M, et.al. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants., Eur J Cancer, 2023. 181: p. 102-118., https://pubmed.ncbi.nlm.nih.gov/36652889/

361. Cordonnier, C, Mikulska, M, Einarsdottir, S, Cesaro, S, Ljungman, P, 2017 ECIL 7 vaccine guidelines., Lancet Infect Dis, 2019. 19 (7): p. 694-695., https://pubmed.ncbi.nlm.nih.gov/31250818/

362. Salmanton-García, J, Marchesi, F, Glenthøj, A, Bilgin, YM, van Praet, J, Dávila-Valls, J, et.al. Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report., Hemasphere, 2022. 6 (11): p. e789., https://pubmed.ncbi.nlm.nih.gov/36310756/

363. Pagano, L, Salmanton-García, J, Marchesi, F, Blennow, O, Gomes da Silva, M, Glenthøj, A, et.al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey., Blood, 2022. 140 (26): p. 2773-2787., https://pubmed.ncbi.nlm.nih.gov/36126318/

364. Piechotta, V, Mellinghoff, SC, Hirsch, C, Brinkmann, A, Iannizzi, C, Kreuzberger, N, et.al. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review., Blood Cancer J, 2022. 12 (5): p. 86., https://pubmed.ncbi.nlm.nih.gov/35641489/

365. Villa, D, Gubbay, J, Sutherland, DR, Laister, R, McGeer, A, Cooper, C, et.al. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant., Leuk Lymphoma, 2013. 54 (7): p. 1387-95., https://pubmed.ncbi.nlm.nih.gov/23240909/

366. Svensson, T, Kättström, M, Hammarlund, Y, Roth, D, Andersson, PO, Svensson, M, et.al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group., Vaccine, 2018. 36 (25): p. 3701-3707., https://pubmed.ncbi.nlm.nih.gov/29748028/

367. Mullane, KM, Morrison, VA, Camacho, LH, Arvin, A, McNeil, SA, Durrand, J, et.al. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial., Lancet Infect Dis, 2019. 19 (9): p. 1001-1012., https://pubmed.ncbi.nlm.nih.gov/31399378/

368. Mullane, KM, Winston, DJ, Wertheim, MS, Betts, RF, Poretz, DM, Camacho, LH, et.al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults., J Infect Dis, 2013. 208 (9): p. 1375-85., https://pubmed.ncbi.nlm.nih.gov/23908479/

369. Dagnew, AF, Ilhan, O, Lee, WS, Woszczyk, D, Kwak, JY, Bowcock, S, et.al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis., Lancet Infect Dis, 2019. 19 (9): p. 988-1000., https://pubmed.ncbi.nlm.nih.gov/31399377/

370. Sodhi, JS, Raja, W, Zargar, SA, Showkat, A, Parveen, S, Nisar, S, et.al. The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy., Indian J Gastroenterol, 2015. 34 (5): p. 372-9., https://pubmed.ncbi.nlm.nih.gov/26531066/

371. Lee, LYW, Starkey, T, Ionescu, MC, Little, M, Tilby, M, Tripathy, AR, et.al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study., Lancet Oncol, 2022. 23 (6): p. 748-757., https://pubmed.ncbi.nlm.nih.gov/35617989/

372. Bergman, P, Blennow, O, Hansson, L, Mielke, S, Nowak, P, Chen, P, et.al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial., EBioMedicine, 2021. 74: p. 103705., https://pubmed.ncbi.nlm.nih.gov/34861491/

373. Debie, Y, Vandamme, T, Goossens, ME, van Dam, PA, Peeters, M, Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer., Eur J Cancer, 2022. 163: p. 177-179., https://pubmed.ncbi.nlm.nih.gov/35077960/

374. Mellinghoff, SC, Mayer, L, Robrecht, S, Weskamm, LM, Dahlke, C, Gruell, H, et.al. SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia., Haematologica, 2022. 107 (10): p. 2480-2484., https://pubmed.ncbi.nlm.nih.gov/35734927/

375. Blixt, L, Wullimann, D, Aleman, S, Lundin, J, Chen, P, Gao, Y, et.al. T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial., Haematologica, 2022. 107 (4): p. 1000-1003., https://pubmed.ncbi.nlm.nih.gov/35045694/

376. Lee, HK, Hoechstetter, MA, Buchner, M, Pham, TT, Huh, JW, Müller, K, et.al. Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination., Blood Adv, 2023. 7 (10): p. 2214-2227., https://pubmed.ncbi.nlm.nih.gov/36630562/

377. Shen, Y, Freeman, JA, Holland, J, Naidu, K, Solterbeck, A, Van Bilsen, N, et.al. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion., Blood, 2022. 140 (25): p. 2709-2721., https://pubmed.ncbi.nlm.nih.gov/36206503/

378. Koch J, Piechotta V, Berner R, Bogdan C, Burchard G, Heininger U, Hummers E, von Kries R, Ledig T, Littmann M, Meerpohl J, Mertens T, Röbl-Mathieu M, van der Sande M, Sander L E, Terhardt M, Überla K, Vygen-Bonnet S, Wichmann O, Wicker S, WiedermannSchmidt U, Widders G, Zepp F, Empfehlung der STIKO zur Implementierung der COVID-19-Impfung in die Empfehlungen der STIKO 2023 und die dazugehörige wissenschaftliche BegründungEpid Bull, 2023. 21: p. 7-48.

379. Rapezzi, D, Sticchi, L, Racchi, O, Mangerini, R, Ferraris, AM, Gaetani, GF, Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma., Eur J Haematol, 2003. 70 (4): p. 225-30., https://pubmed.ncbi.nlm.nih.gov/12656745/

380. Cheuk, DK, Chiang, AK, Lee, TL, Chan, GC, Ha, SY, Vaccines for prophylaxis of viral infections in patients with hematological malignancies., Cochrane Database Syst Rev, 2011. (3): p. CD006505., https://pubmed.ncbi.nlm.nih.gov/21412895/

381. van der Velden, AM, Mulder, AH, Hartkamp, A, Diepersloot, RJ, van Velzen-Blad, H, Biesma, DH, Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients., Eur J Intern Med, 2001. 12 (5): p. 420-424., https://pubmed.ncbi.nlm.nih.gov/11557327/

382. Sun, C, Gao, J, Couzens, L, Tian, X, Farooqui, MZ, Eichelberger, MC, et.al. Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib., JAMA Oncol, 2016. 2 (12): p. 1656-1657., https://pubmed.ncbi.nlm.nih.gov/27533065/

383. Berglund, A, Willén, L, Grödeberg, L, Skattum, L, Hagberg, H, Pauksens, K, The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab., Acta Oncol, 2014. 53 (9): p. 1212-20., https://pubmed.ncbi.nlm.nih.gov/24865118/

384. Douglas, AP, Trubiano, JA, Barr, I, Leung, V, Slavin, MA, Tam, CS, Ibrutinib may impair serological responses to influenza vaccination., Haematologica, 2017. 102 (10): p. e397-e399., https://pubmed.ncbi.nlm.nih.gov/28659336/

385. DiazGranados, CA, Dunning, AJ, Kimmel, M, Kirby, D, Treanor, J, Collins, A, et.al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults., N Engl J Med, 2014. 371 (7): p. 635-45., https://pubmed.ncbi.nlm.nih.gov/25119609/

386. Hsiao, A, Yee, A, Fireman, B, Hansen, J, Lewis, N, Klein, NP, Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age., N Engl J Med, 2023. 389 (24): p. 2245-2255., https://pubmed.ncbi.nlm.nih.gov/38091531/

387. Muchtar, E, Koehler, AB, Johnson, MJ, Rabe, KG, Ding, W, Call, TG, et.al. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis., Am J Hematol, 2022. 97 (1): p. 90-98., https://pubmed.ncbi.nlm.nih.gov/34699616/

388. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., et.al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, Lancet, 2010. 376 (9747): p. 1164-74., https://www.ncbi.nlm.nih.gov/pubmed/20888994

389. Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., et.al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions, N Engl J Med, 2014. 370 (12): p. 1101-10., https://www.ncbi.nlm.nih.gov/pubmed/24401022

390. Tsimberidou, A. M., Wen, S., McLaughlin, P., O'Brien, S., Wierda, W. G., Lerner, S., et.al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma, J Clin Oncol, 2009. 27 (6): p. 904-10., https://www.ncbi.nlm.nih.gov/pubmed/19114699

391. Eichhorst, B. F., Fischer, K., Fink, A. M., Elter, T., Wendtner, C. M., Goede, V., et.al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis, Blood, 2011. 117 (6): p. 1817-21., https://www.ncbi.nlm.nih.gov/pubmed/21139079

392. Schollkopf, C., Rosendahl, D., Rostgaard, K., Pipper, C., Hjalgrim, H., Risk of second cancer after chronic lymphocytic leukemia, Int J Cancer, 2007. 121 (1): p. 151-6., https://www.ncbi.nlm.nih.gov/pubmed/17351903

393. Ramsay, A. G., Clear, A. J., Fatah, R., Gribben, J. G., Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer, Blood, 2012. 120 (7): p. 1412-21., https://www.ncbi.nlm.nih.gov/pubmed/22547582

394. Frisch, M., Biggar, R. J., Engels, E. A., Goedert, J. J., Group, A. IDS-Cancer Match Registry Study, Association of cancer with AIDS-related immunosuppression in adults, JAMA, 2001. 285 (13): p. 1736-45., https://www.ncbi.nlm.nih.gov/pubmed/11277828

395. Gallagher, M. P., Kelly, P. J., Jardine, M., Perkovic, V., Cass, A., Craig, J. C., et.al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation, J Am Soc Nephrol, 2010. 21 (5): p. 852-8., https://www.ncbi.nlm.nih.gov/pubmed/20431040

396. Beiggi, S., Johnston, J. B., Seftel, M. D., Pitz, M. W., Kumar, R., Banerji, V., et.al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study, British Journal of Cancer, 2013. 109: p. 1287-90., https://www.ncbi.nlm.nih.gov/pubmed/23860531

397. Maurer, C., Langerbeins, P., Bahlo, J., Cramer, P., Fink, A. M., Pflug, N., et.al. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL, Leukemia, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27133817

398. Royle, J. A., Baade, P. D., Joske, D., Girschik, J., Fritschi, L., Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study, British Journal of Cancer, 2011. 105 (7): p. 1076-81., https://www.ncbi.nlm.nih.gov/pubmed/21847118

399. Morrison, V. A., Rai, K. R., Peterson, B. L., Kolitz, J. E., Elias, L., Appelbaum, F. R., et.al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011, J Clin Oncol, 2002. 20 (18): p. 3878-84., https://www.ncbi.nlm.nih.gov/pubmed/12228208

400. Colovic, M., Suvajdzic, N., Jankovic, G., Tomin, D., Colovic, N., Fekete, M. D., et.al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide, Biomedicine & Pharmacotherapy, 2011. 65 (5): p. 319-21., https://www.ncbi.nlm.nih.gov/pubmed/21775097

401. Zhou, Y., Tang, G., Medeiros, L. J., McDonnell, T. J., Keating, M. J., Wierda, W. G., et.al. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, Mod Pathol, 2012. 25 (2): p. 237-45., https://www.ncbi.nlm.nih.gov/pubmed/22080061

402. Smith, M. R., Neuberg, D., Flinn, I. W., Grever, M. R., Lazarus, H. M., Rowe, J. M., et.al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997, Blood, 2011. 118 (13): p. 3525-7., https://pubmed.ncbi.nlm.nih.gov/21803850/

403. Knips, L, Bergenthal, N, Streckmann, F, Monsef, I, Elter, T, Skoetz, N, Aerobic physical exercise for adult patients with haematological malignancies., Cochrane Database Syst Rev, 2019. 1 (1): p. CD009075., https://pubmed.ncbi.nlm.nih.gov/30702150/

404. Voskuil, DW, van Nes, JGH, Junggeburt, JMC, van de Velde, CJH, van Leeuwen, FE, de Haes, JCJM, Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients., Ann Oncol, 2010. 21 (10): p. 2094-2101., https://pubmed.ncbi.nlm.nih.gov/20357033/

405. D'Arena, G., Laurenti, L., Coscia, M., Cortelezzi, A., Chiarenza, A., Pozzato, G., et.al. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey, Leuk Lymphoma, 2014. 55 (4): p. 841-7., https://www.ncbi.nlm.nih.gov/pubmed/23829282

406. S3-Leitlinie Komplementärmedizin in der Behandlung onkologischer PatientInnen, 2021., https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin

407. Rueffer JU, D.F., Fatigue – das tumorbedingte Erschöpfungssyndrom.In Weiss J & Brähler E (Hrsg.). Psychoonkologie in Forschung und Praxis. Schattauer GmbH, Stuttgart, 2013. p. 33 - 44.

408. Rick, O., Kognitive Dysfunktion bei Krebspatienten.Focus Onkologie, 2017. 20 (6): p. 34-37.

409. (BAR) B.f.R.e.V., Rehabilitation. Vom Antrag bis zur Nachsorge - für Ärzte, Psychologische Psychotherapeuten und andere Gesundheitsberufe., 2018.

410. Bennett, S, Pigott, A, Beller, EM, Haines, T, Meredith, P, Delaney, C, Educational interventions for the management of cancer-related fatigue in adults., Cochrane Database Syst Rev, 2016. 11 (11): p. CD008144., https://pubmed.ncbi.nlm.nih.gov/27883365/

411. Heim, M., Onkologische Rehabilitation: Wege zurück ins LebenHämatologie & Onkologie, 2008. p. 8 - 12.

412. Kähnert, H, Exner, AK, Brand, S, Leibbrand, B, [Development and Evaluation of the Work-Related Intervention "Perspective Job" for the Oncological Rehabilitation]., Rehabilitation (Stuttg), 2016. 55 (3): p. 150-6., https://pubmed.ncbi.nlm.nih.gov/27284730/

413. Cramp, F, Byron-Daniel, J, Exercise for the management of cancer-related fatigue in adults., Cochrane Database Syst Rev, 2012. 11 (11): p. CD006145., https://pubmed.ncbi.nlm.nih.gov/23152233/

414. Mehnert-Theuerkauf, Anja, Härter, Martin, Koch, Uwe, Long-term effects of cancer. Aftercare and rehabilitation requirements, 2012. 55: p. 509 - 15., https://doi.org/10.1007/s00103-012-1447-x

415. Mehnert, A, Koch, U, Predictors of employment among cancer survivors after medical rehabilitation--a prospective study., Scand J Work Environ Health, 2013. 39 (1): p. 76-87., https://pubmed.ncbi.nlm.nih.gov/22422040/

416. Verbeek, J, Spelten, E, Kammeijer, M, Sprangers, M, Return to work of cancer survivors: a prospective cohort study into the quality of rehabilitation by occupational physicians., Occup Environ Med, 2003. 60 (5): p. 352-7., https://pubmed.ncbi.nlm.nih.gov/12709521/

417. de Boer, AG, Taskila, T, Ojajärvi, A, van Dijk, FJ, Verbeek, JH, Cancer survivors and unemployment: a meta-analysis and meta-regression., JAMA, 2009. 301 (7): p. 753-62., https://pubmed.ncbi.nlm.nih.gov/19224752/

418. McGrath, PD, Hartigan, B, Holewa, H, Skarparis, M, Returning to work after treatment for haematological cancer: findings from Australia., Support Care Cancer, 2012. 20 (9): p. 1957-64., https://pubmed.ncbi.nlm.nih.gov/22033835/

419. Roelen, CA, Koopmans, PC, Groothoff, JW, van der Klink, JJ, Bültmann, U, Return to work after cancer diagnosed in 2002, 2005 and 2008., J Occup Rehabil, 2011. 21 (3): p. 335-41., https://pubmed.ncbi.nlm.nih.gov/21796373/

420. Bürger, W., Positive und gesundheitsförderliche Aspekte der Arbeit und ihre Bedeutung für Patienten in medizinischer RehabilitationZeitschrift für Gesundheitspsychologie, 1998. 6(3): p. 137 - 150.

421. Bund, Deutsche Rentenversicherung, Arbeits-und berufsbezogene Orientierung in der medizinischen Rehabilitation–Praxishandbuch, 2011.

422. Manteuffel, Leonie von, Medizinische Rehabilitation: Berufliche Teilhabe als Leitziel., 2011. 108(4): p. A-154 - A-156., https://www.aerzteblatt.de/archiv/80534/Medizinische-Rehabilitation-Berufliche-Teilhabe-als-Leitziel

423. Peteet, JR, Cancer and the meaning of work., Gen Hosp Psychiatry, 2000. 22 (3): p. 200-5., https://pubmed.ncbi.nlm.nih.gov/10880715/

424. Böttcher, HM, Steimann, M, Rotsch, M, Zurborn, KH, Koch, U, Bergelt, C, Occupational stress and its association with early retirement and subjective need for occupational rehabilitation in cancer patients., Psychooncology, 2013. 22 (8): p. 1807-14., https://pubmed.ncbi.nlm.nih.gov/23175474/

425. Feuerstein, M, Todd, BL, Moskowitz, MC, Bruns, GL, Stoler, MR, Nassif, T, et.al. Work in cancer survivors: a model for practice and research., J Cancer Surviv, 2010. 4 (4): p. 415-37., https://pubmed.ncbi.nlm.nih.gov/20945110/

426. Wienert, J, Bethge, M, [Work-Related Medical Rehabilitation in Cancer Rehabilitation - Short-Term Results from a Cluster-Randomized Multicenter-Trial]., Rehabilitation (Stuttg), 2019. 58 (3)(3): p. 181-190., https://pubmed.ncbi.nlm.nih.gov/29801187/

427. Sautier, LP, Scherwath, A, Weis, J, Sarkar, S, Bosbach, M, Schendel, M, et.al. [Assessment of Work Engagement in Patients with Hematological Malignancies: Psychometric Properties of the German Version of the Utrecht Work Engagement Scale 9 (UWES-9)]., Rehabilitation (Stuttg), 2015. 54 (5)(5): p. 297-303., https://pubmed.ncbi.nlm.nih.gov/26505182/

428. Bürger, W, Deck, R, [SIBAR - a short screening instrument for the assessment of need for occupation related treatment in medical rehabilitation]., Rehabilitation (Stuttg), 2009. 48 (4): p. 211-21., https://pubmed.ncbi.nlm.nih.gov/19688659/

429. Mehnert, A, Employment and work-related issues in cancer survivors., Crit Rev Oncol Hematol, 2011. 77 (2): p. 109-30., https://pubmed.ncbi.nlm.nih.gov/20117019/

430. Mehnert, A, Barth, J, Gaspar, M, Leibbrand, B, Kegel, CD, Bootsveld, W, et.al. Predictors of early retirement after cancer rehabilitation-a longitudinal study., Eur J Cancer Care (Engl), 2017. 26 (5):, https://pubmed.ncbi.nlm.nih.gov/27334307/

431. Holtzer-Goor, K. M., Schaafsma, M. R., Joosten, P., Posthuma, E. F., Wittebol, S., Huijgens, P. C., et.al. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study, Qual Life Res, 2015. 24 (12): p. 2895-906., https://www.ncbi.nlm.nih.gov/pubmed/26205768

432. Trevino, KM, Martin, P, Chen, Z, Leonard, JP, Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study., Clin Lymphoma Myeloma Leuk, 2022. 22 (2): p. 82-88., https://pubmed.ncbi.nlm.nih.gov/34479847/

433. Shanafelt, T. D., Bowen, D., Venkat, C., Slager, S. L., Zent, C. S., Kay, N. E., et.al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients, Br J Haematol, 2007. 139 (2): p. 255-64., https://www.ncbi.nlm.nih.gov/pubmed/17897301

434. Youron, P, Singh, C, Jindal, N, Malhotra, P, Khadwal, A, Jain, A, et.al. Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire., Eur J Haematol, 2020. 105 (6): p. 755-762., https://pubmed.ncbi.nlm.nih.gov/32748412/

435. McCaughan, D, Roman, E, Smith, AG, Garry, AC, Johnson, MJ, Patmore, RD, et.al. Haematology nurses' perspectives of their patients' places of care and death: A UK qualitative interview study., Eur J Oncol Nurs, 2019. 39: p. 70-80., https://pubmed.ncbi.nlm.nih.gov/30850141/

436. McCaughan, D, Roman, E, Smith, AG, Garry, AC, Johnson, MJ, Patmore, RD, et.al. Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study., Palliat Med, 2019. 33 (5): p. 518-530., https://pubmed.ncbi.nlm.nih.gov/30696347/

437. Odejide, OO, Cronin, AM, Condron, NB, Fletcher, SA, Earle, CC, Tulsky, JA, et.al. Barriers to Quality End-of-Life Care for Patients With Blood Cancers., J Clin Oncol, 2016. 34 (26): p. 3126-32., https://pubmed.ncbi.nlm.nih.gov/27400944/

438. Oerlemans, S, Efficace, F, Kieffer, JM, Kyriakou, C, Xochelli, A, Levedahl, K, et.al. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia., Br J Haematol, 2022. 197 (4): p. 431-441., https://pubmed.ncbi.nlm.nih.gov/35255152/

439. van de Poll-Franse, L, Oerlemans, S, Bredart, A, Kyriakou, C, Sztankay, M, Pallua, S, et.al. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia., Qual Life Res, 2018. 27 (2): p. 333-345., https://pubmed.ncbi.nlm.nih.gov/29127596/

440. Alt-Epping, B, Nauck, F, Schneider, N, Leben bis zuletzt. Hausärztliche und spezialisierte Palliativversorgung bei schwerstkranken Patienten.Der Hausarzt, 2012. 11: p. 43 - 46.

441. Adler, K, Schlieper, D, Kindgen-Milles, D, Meier, S, Schwartz, J, van Caster, P, et.al. [Integration of palliative care into intensive care : Systematic review]., Anaesthesist, 2017. 66 (9): p. 660-666., https://pubmed.ncbi.nlm.nih.gov/28589374/

442. Dalgaard, KM, Bergenholtz, H, Nielsen, ME, Timm, H, Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome., Palliat Support Care, 2014. 12 (6): p. 495-513., https://pubmed.ncbi.nlm.nih.gov/24621947/

443. Davis, MP, Temel, JS, Balboni, T, Glare, P, A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses., Ann Palliat Med, 2015. 4 (3): p. 99-121., https://pubmed.ncbi.nlm.nih.gov/26231807/

444. Hui, D, Kim, YJ, Park, JC, Zhang, Y, Strasser, F, Cherny, N, et.al. Integration of oncology and palliative care: a systematic review., Oncologist, 2015. 20 (1): p. 77-83., https://pubmed.ncbi.nlm.nih.gov/25480826/

445. Hui, D, Meng, YC, Bruera, S, Geng, Y, Hutchins, R, Mori, M, et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review., Oncologist, 2016. 21 (7): p. 895-901., https://pubmed.ncbi.nlm.nih.gov/27185614/

446. Gaertner, J, Siemens, W, Meerpohl, JJ, Antes, G, Meffert, C, Xander, C, et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis., BMJ, 2017. 357: p. j2925., https://pubmed.ncbi.nlm.nih.gov/28676557/

447. Haun, MW, Estel, S, Rücker, G, Friederich, HC, Villalobos, M, Thomas, M, et.al. Early palliative care for adults with advanced cancer., Cochrane Database Syst Rev, 2017. 6 (6): p. CD011129., https://pubmed.ncbi.nlm.nih.gov/28603881/

448. Tassinari, D, Drudi, F, Monterubbianesi, MC, Stocchi, L, Ferioli, I, Marzaloni, A, et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature., Rev Recent Clin Trials, 2016. 11 (1): p. 63-71., https://pubmed.ncbi.nlm.nih.gov/26464077/

449. El-Jawahri, A, Nelson, AM, Gray, TF, Lee, SJ, LeBlanc, TW, Palliative and End-of-Life Care for Patients With Hematologic Malignancies., J Clin Oncol, 2020. 38 (9): p. 944-953., https://pubmed.ncbi.nlm.nih.gov/32023164/